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Summary 
            
Point mutations within the histone H3.3 are frequent in aggressive childhood brain tumours 
known as paediatric high-grade gliomas (pHGGs). Intriguingly, different mutations arise in 
discrete anatomical regions: H3.3-G34R within the forebrain and H3.3-K27M preferentially 
within the hindbrain. The reasons for this contrasting aetiology are unknown. By engineering 
human foetal neural stem cell cultures from distinct regions, we demonstrate here that cell-intrinsic 
regional identity provides differential responsiveness to each mutant that mirrors the origins of 
pHGGs. Focusing on H3.3-G34R, we find that the oncohistone supports proliferation of forebrain 
cells, while inducing a cytostatic response in the hindbrain. Mechanistically, H3.3-G34R does not 
impose widespread transcriptional or epigenetic changes, but impairs recruitment of ZMYND11, 
a transcriptional repressor of highly expressed genes. We therefore propose that H3.3-G34R 
promotes tumorigenesis by stabilising the expression of key progenitor genes and, thus, locking 













Genetic disruptions in chromatin-regulating pathways have been identified across many adult and 
paediatric tumours, thereby providing direct evidence for the critical role of epigenetic 
dysregulation in driving cancer (Filbin and Monje, 2019; Mohammad and Helin, 2017; Valencia 
and Kadoch, 2019; Weinberg et al., 2017). A seminal discovery in the field was the identification 
of recurrent mutations affecting histone H3 and epigenetic regulatory proteins in paediatric cancers 
(Schwartzentruber et al., 2012; Wu et al., 2012). Unique to pHGGs – universally lethal childhood 
brain tumours (Jones et al., 2016) – are mutations in H3F3A, which encodes the replication-
independent histone H3.3 (Ahmad and Henikoff, 2002). Two single-copy mutations occur within 
the histone tail and typically give rise to substitution of either lysine 27 to methionine (K27M), or 
glycine 34 to arginine (G34R) (Schwartzentruber et al., 2012; Wu et al., 2012). 
  
Intriguingly, K27M and G34R mutations are mutually exclusive and have a distinct anatomical 
distribution within the central nervous system (CNS); K27M is typically found in brainstem 
tumours (hindbrain-derived), while G34R occurs exclusively in hemispheric tumours (forebrain-
derived) (Mackay et al., 2017; Sturm et al., 2012). Biochemically, H3.3-K27M has been shown to 
inhibit PRC2 (Polycomb Repressive Complex 2) (Lewis et al., 2013), while H3.3-G34R is thought 
to disrupt methylation of H3K36 (Lewis et al., 2013; Voon et al., 2018). However, the exact 
cellular and epigenetic mechanisms by which these ‘oncohistones’ operate during initiation of 
pHGGs and the reasons for their restricted anatomical specificity remain unknown (Filbin and 
Monje, 2019; Mohammad and Helin, 2017; Weinberg et al., 2017). 
  
Here, we explore why these mutations arise with such anatomical precision. Of note, H3F3A is 
ubiquitously expressed across various tissues and we found no evidence of differential levels in 
the developing human CNS that could explain the biased distribution of the mutations (Figure S1). 
Based on the observation that H3.3 mutant tumours express region-specific neurodevelopmental 
signatures that correlate with their location (Mackay et al., 2017; Sturm et al., 2012), we 
hypothesised that transcriptional programs associated with regionalisation of the developing brain 
provide the critical cell-intrinsic vulnerabilities for each distinct H3.3 mutant.  
 
To test this, we isolated primary human neural stem cells (NSCs) from forebrain and hindbrain 
regions of the developing human brain and engineered H3.3 and associated driver mutations. Using 
this model system, we demonstrate that hindbrain cells are more susceptible to H3.3-K27M 
oncogenic effects, whereas forebrain NSCs have a unique competence to respond to H3.3-G34R. 
We then focussed on H3.3-G34R – which has been less explored than H3.3-K27M – and explored 
its mechanism of action and reasons for the forebrain selectivity. Using both the engineered foetal 
NSC models and patient-derived cells, we demonstrate that H3.3-G34R does not induce pervasive 
transcriptional or epigenetic changes, but rather reinforces the preexisting progenitor state of the 
putative forebrain cell-of-origin. Mechanistically, we show that the G34R mutation impairs 
binding of H3.3 to the transcriptional repressor ZMYND11, which we propose acts focally to 



















Human foetal primary NSCs cultures retain their regional identity and recapitulate 
transcriptional signatures of pHGGs. 
We reasoned that human foetal NSC cultures (Conti et al., 2005; Sun et al., 2008) derived from 
anatomically relevant regions could provide a tractable experimental system to model cell-intrinsic 
responses to H3.3 mutations. This allows investigation of early responses in an appropriate human 
cellular context, without the confounding influences of region-specific microenvironmental or 
broader systemic cues inherent to in vivo systems. We therefore derived primary NSC cultures 
from various regions of the developing human CNS (Figure 1A; see methods) and used these to 
assess the initial phenotypic responses to H3.3-K27M or H3.3-G34R oncohistones in vitro. 
  
Established cultures uniformly expressed NESTIN, SOX2 and other pan-NSC markers (Figure 
S2A-B) and could be expanded using culture conditions that support self-renewal (Conti et al., 
2005). Importantly, mRNA-profiling (RNA-seq) revealed that key forebrain and hindbrain 
transcriptional signatures that define the primary tissue samples were retained in the matched NSC 
cultures: forebrain-specific markers (e.g. FOXG1, DLX2/6, EMX2) were highly expressed in 
neocortex and striatum NSCs, while posterior markers (e.g. IRX1/2 and HOX genes) were 
expressed in brainstem and spinal cord cultures (Figure 1B-D and Figure S2C).  
  
To determine whether the region-specific foetal transcriptional signatures were relevant to pHGGs, 
we next compared our dataset with published primary tumour transcriptomes from three 
independent cohorts (Paugh et al., 2010; Schwartzentruber et al., 2012; Sturm et al., 2012).  Indeed, 
through clustering approaches, the forebrain and hindbrain signatures successfully segregated the 
tumour samples based on H3.3 mutation status (Figure 1E-F; Table S1). Conversely, K27M- and 
G34R- tumour signatures distinguished the foetal tissue and matched NSC cultures based on their 
region-of-origin (Figure S2D-E; Table S1).  
  
We next used single-sample gene set enrichment analysis (ssGSEA) to assess whether the pHGG 
subtype-specific signatures were specifically captured in the established NSC lines. Indeed, we 
observed enrichment of the G34R-associated signature in cultured neocortex and striatum NSCs, 
while the defining K27M signature was preferentially enriched in brainstem and spinal cord 
cultures (Figure 1G-H). Consistent with this, neocortex and striatum cell line-specific gene sets 
were specifically enriched in G34R-mutant tumours, and brainstem and spinal cord NSC 
signatures in K27M tumours (Figure 1I). Thus, despite being expanded in identical culture 
conditions, NSC cultures largely retain their forebrain-hindbrain regional identities and 
recapitulate key transcriptional signatures that define pHGG subgroups.  
 
Phenotypic responses to distinct H3.3 oncohistones mirrors their anatomical selectivity in 
pHGGs. 
As the aforementioned results attested the relevance of our in vitro models for exploring pHGG 
aetiology, we next set out to evaluate the impact of cell-intrinsic regional identity on the cellular 
responses to H3.3 mutants. We first focussed on H3.3-K27M as a previous study using mouse 
models suggests preferential oncogenic activity of K27M in the hindbrain compartment (Larson 
et al., 2019). We induced stable expression of either wild-type (WT) or K27M mutant H3.3 using 
the PiggyBac transposon system in forebrain (neocortex or striatum) and hindbrain (brainstem) 
NSC cultures derived from two independent human foetal specimens (GCGR-NS19 and GCGR-
NS13, see methods). A V5 epitope tag was fused to C-terminus of the construct to allow tracking 
of the ectopically expressed H3.3 protein (Figure 2A). Consistent with the reported biochemical 
activity of H3.3-K27M, we found substantial loss of global H3K27me3 in all lines, regardless of 
regional identity (Figure 2A). Phenotypically, however, overt oncogenic activity – i.e. increased 
proliferation and clonogenicity as well reduced senescence-associated βgalactosidase (SA-βgal) – 
was only observed in the brainstem, but not forebrain NSCs (Figure 2B-D). This indicates that 
global reduction of H3K27me3 alone is not sufficient to induce cellular responses and that H3.3-
K27M tumour initiation may require a specific developmental cellular context. In a parallel study, 
we have characterised transcriptional and chromatin landscape changes in response to H3.3-K27M 
in these brainstem foetal NSCs (Brien and Bressan et al., submitted). 
 
Given that region-specific cellular responses recapitulated the aetiology of H3.3-K27M pHGGs, 
we next focussed on understanding the less well studied H3.3-G34R mutant, for which mechanistic 
insights remain elusive and no models of tumour initiation are currently available to understand 
regional selectivity. Using the same experimental approach, however, we found that the G34R 
mutant does not induce any overt proliferative effects in forebrain cultures (Figure 3A-E, Figure 
S3A-C). In contrast, in brainstem cultures, H3.3-G34R surprisingly triggered a cytostatic response 
with reductions in EdU incorporation and colony formation, as well as an increase in SA-βgal 
activity (Figure 3B-E). Together, our data indicate that, while forebrain cells can tolerate H3.3-
G34R, hindbrain NSCs are intrinsically protected against its oncogenic effect, potentially 
explaining the absence of G34R-mutant tumours in posterior locations.  
  
Due to the lack of overt phenotypic responses to H3.3-G34R in forebrain-derived NSCs, we 
reasoned that, even in an appropriate developmental context, cooperating mutations are required 
for manifestation of its oncogenic effects. We therefore introduced two additional oncogenic 
alterations commonly found in pHGGs: PDGFRA amplification and TP53 loss-of-function 
(Mackay et al., 2017) (Figure 3F, hereafter referred to as PP5W or PP5G, for PDGFRA 
overexpression, P53 knockout and WT or G34R mutant H3.3, respectively). Indeed, compared to 
the WT H3.3 control (PP5W), neocortical PP5G cells displayed increased proliferation and 
clonogenicity, as well as a reduction in SA-βgal activity (Figure 3G). Upon transplantation into 
the cerebral hemisphere of immunocompromised mice, neocortical PP5G cells formed highly 
infiltrative neoplastic lesions confirming the anticipated role for H3.3-G34R in tumour initiation 
(Figure 3H-I). In stark contrast, engineering of PP5G mutations in brainstem NSCs triggered a 
strong cytostatic response compared to the PP5W control (Figure 3G) and did not render the cells 
tumour-initiating (data not shown). Similarly, combined engineering of TP53 knockout and H3.3-
G34R, without PDGFRA overexpression, also increased the proliferation of neocortical cultures, 
while inducing a cytostatic response in the brainstem counterpart (Figure S3D-F).  
 
In summary, these findings demonstrate that, despite the identical culture conditions and 
similarities in broad NSC definition, regionally-distinct foetal NSCs display profound differences 
in their cell-intrinsic responses to oncohistones. Together, these highlight the importance of the 
regional identity in providing competence to distinct H3.3 mutations, which may explain the 
unique anatomical distribution of pHGGs in patients.  
 
H3.3-G34R reinforces the transcriptional circuits that define forebrain identity 
The preceding data suggested a role for H3.3-G34R in cooperation with other drivers within the 
forebrain. We next sought to investigate the effect of H3.3-G34R in fully transformed patient-
derived tumour cells by eliminating the oncogenic allele and subsequent dissection of key 
downstream consequences in isogenic matched pairs. To that end, we used the CRISPR/Cas9 
system to genetically inactivate the H3F3A G34R-mutant allele in a previously described mutant 
cell line (pGBM002) derived from a hemispheric (forebrain) patient tumour (Hennika et al., 2017) 
(Figure 4A, Figure S4A-B). Similarly to the primary forebrain NSC cultures, the patient cells 
uniformly expressed the NSC markers SOX2 and NESTIN and transcriptionally resembled the 
foetal forebrain. In addition, immunoblotting analysis indicated absence of ATRX protein, a H3.3 
chaperone often mutated in G34R pHGGs (Mackay et al., 2017) (Figure S4A).  
 
Following delivery of a mutant allele-specific sgRNA, five independent H3.3-G34R knock-out 
(G34R-KO) clonal lines were isolated and functionally characterised (Figure 4B-G). Compared to 
the parental cells, each displayed a similar phenotype, with slightly slower proliferation, reduced 
clonogenicity, and accumulation of SA-βgal-positive cells (Figure 4C-G). Importantly, in vitro 
overexpression of V5-tagged G34R-H3.3, but not WT-H3.3, was able to rescue the proliferative 
effect, thus validating the specificity of the knockout experiment  (Figure S4C). 
  
To dissect the mechanisms underlying the oncogenic effect of H3.3-G34R, we next defined the 
key transcriptional changes through mRNA-seq in the parental pGBM002 cells and G34R-KO 
clones (Figure 4I-L). Consistent with the cellular responses, principal component analysis 
confirmed separation of the G34R-KO clones as a distinct cluster from the parental cells (Figure 
4I). Interestingly, we observed significant downregulation of many genes associated with forebrain 
development and neuroprogenitor proliferation in the G34R-KO cells, including CDK6 (Mi et al., 
2013), SOX1/2 (Pevny and Placzek, 2005), POU3F2/3 (Castro et al., 2006), ARX (Kitamura et al., 
2002) and DMRTA2 (Konno et al., 2012; Young et al., 2017) (Figure 4J-L). We identified only a 
marginal reduction in the expression of MYCN, a previously suggested target of H3.3-G34R based 
on differential expression analysis of non-isogenic tumour cell lines (Bjerke et al, 2013). 
 
Analysis of transcriptomic data from patient tumour samples demonstrated that many of these 
forebrain-related genes were also more highly expressed in H3.3-G34R-mutant than H3.3-WT 
tumours of hemispheric location (Figure 4M, Figure S4D). Altogether, these findings suggest that 
H3.3-G34R acts cell-autonomously to reinforce or stabilise a specific forebrain regulatory circuit 
present in  the cell-of-origin. In agreement, we found that key transcription factor genes involved 
in neuroprogenitor self-renewal/proliferation were also upregulated in the engineered foetal 
neocortex model (PP5G vs PP5W cells, Figure S3G-H). These included the neuroprogenitor 
markers OLIG2 and SOX3, as well as the forebrain-specific factors EMX2, NR2F1, HOPX, 
DMRTA2 and HIVEP2 (Bertacchi et al., 2020; Zweifel et al., 2018; Steinfeld et al., 2016; Ono et 
al., 2008; Yoshida et al., 1997). Of those, we note that DMRTA2, EMX2, NR2F1 and HIVEP2 were 
shared between engineered neocortex and patient-derived models, and may be part of a core 
regulatory network impacted by H3.3-G34R. 
 
By contrast, no alterations in the expression of forebrain neural progenitor-related genes were 
observed in the engineered PP5W/G brainstem NSCs. Instead, transcriptional profiling indicated 
only modest global transcriptional changes (Figure S3H); however, most notably we observed a 
robust upregulation of the senescence effector and tumour-suppressor gene CDKN1A (encoding 
p21) (Abbas and Dutta, 2009). Intriguingly, no significant transcriptional changes were observed 
in the single mutant neocortex cells (G34R vs WT H3.3; Figure S3H), suggesting that 
manifestation of the H3.3-G34R effects at the transcriptional level might also require additional 
oncogenic signalling. Thus, we surmise that H3.3-G34R, in contrast to H3.3-K27M, requires 
additional oncogenic signalling for phenotypic activity and does not induce widespread 
transcriptomic changes. It instead appears to reinforce the pre-existing progenitor state of the 
forebrain cell-of-origin through increased expression of key transcriptional regulatory genes.  
 
H3.3-G34R incorporates at pre-existing active genes and does not induce global changes in 
chromatin marks 
We next capitalised on our patient-derived isogenic models to dissect the molecular mechanism 
underlying H3.3-G34R activity. In agreement with previously reported biochemical analyses 
(Lewis et al. 2013), we did not detect dramatic changes in total histone H3 post-translational 
modifications, supporting the idea that, unlike H3.3-K27M, H3.3-G34R does not act in a dominant 
manner to disrupt histone modification levels globally (Figure S5A).  
 
To investigate whether G34R-H3.3 causes differential distribution of chromatin modification 
marks, we next mapped the genome-wide distribution of the mutant histone as well as active 
(H3K4me3/H3K36me3) and repressive (H3K27me3) histone marks through ChIP-Seq using 
parental and G34R-KO pGBM002 cells (Figure 5A). Similar to the reported distribution pattern 
of WT H3.3 at euchromatin (Goldberg et al, 2010), we observed higher H3.3-G34R enrichment at 
active promoters and gene bodies, which are marked respectively by high levels of H3K4me3 and 
H3K36me3 (Figure 5B-C, S5B-C). Consistently, H3.3-G34R ChIP reads directly correlated with 
mRNA expression levels, indicating greater levels of H3.3-G34R incorporation at highly 
transcribed genes (Figure 5D-E, S5D). Importantly, using the V5-H3.3 rescued G34R-KO cells, 
we found a strong correlation between WT and G34R V5-H3.3 ChIP signal (Figure 5F-G), 
indicating that the mutation does not grossly affect the H3.3 distribution patterns. 
 
As altered patterns of genome-wide H3.3 distribution appear unlikely to explain the G34R 
transcriptional effects, we next sought to address whether incorporation of the mutant histone 
influenced the deposition patterns of the histone marks. Surprisingly, we did not find any 
significant correlation between G34R-H3.3 enrichment and changes in H3K4me3, H3K36me3 or 
H3K27me3 levels (Figure 5H, Figure S5C), indicating that the G34R mutant does not directly alter 
deposition of major histone marks as described for the other H3.3 oncohistones (Chan et al., 2013; 
Lewis et al., 2013; Fang et al., 2016; Lu et al., 2016; Khazaei et al, 2020). To further validate these 
observations, we next used ChIP peak calling to analyse the distribution of each histone mark at 
their cognate genomic regions; i.e. H3K4me3 and H3K27me3 at gene promoters and H3K36me3 
at gene bodies (Figure 5I). In agreement, we found a large degree overlap of promoter-associated 
H3K4me3 and gene body-associated H3K36me peaks between parental and G34R-KO cells. 
Importantly, closer examination of the identified exclusive peaks (either parental or G34R-KO 
specific) indicated that those were low abundance peaks with only marginally lower levels in the 
reciprocal line (Figure 5I).  Importantly, those differential bound peaks were not associated with 
consistent transcriptional expression changes of the underlying genes (Figure 5J). To a lesser 
extent, a high degree of overlap in repressive promoter-associated H3K27me3 peaks was also 
observed. Importantly, despite the detection of parental or G34R-KO specific peaks, these were 
not associated with major transcriptional changes (Figure 5I-J). A similar pattern of genome-wide 
distribution of the investigated histone marks was also observed in the V5-H3.3 rescued G34R-
KO cells (Figure S6).  
 
These data indicate that, unlike H3.3-K27N and other H3.3 oncogenic forms, H3.3-G34R does not 
induce widespread epigenetic or transcriptional changes, and might instead operate through fine-
tuning of preexisting expressed genes where it accumulates at highest levels. 
 
G34R mutation disrupts binding of H3.3 to transcriptional repressor ZMYND11.  
As H3.3 contributes to a small fraction of the total histone H3 pool within cells, and initial 
biochemical studies indicated that the G34R mutation prevents SETD2-mediated tri-methylation 
of the K36 residue on the mutant histone only (i.e cis loss of K36me3; Lewis et al., 2013; Zhang 
et al., 2017), we speculated that the mutation could impose transcriptional alterations through loss 
of H3.3K36me3 at specific loci. Using immunoprecipitation of the ectopically expressed V5-
tagged H3.3 in G34R-KO rescued cells, we confirmed in a disease-relevant cellular context that 
the G34R mutation indeed causes loss of K36me3 on mutant histone but not on the total H3 pool 
(Figure 6A). In agreement, we found that the most downregulated genes in G34R-KO cells (i.e 
candidate G34R-upregulated targets) had higher than average H3.3-G34R coverage along their 
promoter and gene body regions (Figure 6B). Importantly, H3.3-G34R coverage appears 
particularly higher at the set of forebrain-related genes that are downregulated upon ablation of the 
G34R allele (Figure 6B-C), altogether indicating that H3.3-G34R acts mainly through 
transcriptional upregulation. 
 
To address in an unbiased manner whether differential recruitment of biochemical partners may 
underlie the transcriptional changes imposed by H3.3-G34R, we next performed V5 epitope-based 
pull-down of WT- and G34R-H3.3 in the rescued G34R-KO cells and mass spectrometry to 
identify protein interaction partners (Figure 6D; Table S2). Strikingly, we found that H3.3-G34R 
has reduced binding to ZMYND11, a specific reader of H3.3K36me3 that functions as an 
unconventional transcription co-repressor by modulating elongation and splicing of highly 
expressed genes (Wen et al 2014; Guo et al 2014). Reduced binding to ZMYND11 was also 
confirmed by Co-IP experiments in both patient-derived and engineered forebrain NSC isogenic 
cell line pairs (Figure 6E).   
 
Further supporting the involvement of ZMYND11, we found using computational analyses that 
genes preferentially affected by H3.3-G34R (including the set of key forebrain-associated genes) 
collectively display sequence features, such as higher CpG content and presence of intragenic CpG 
islands (Figure 6F), that are associated with the control of transcriptional elongation and splicing 
(Veloso et al., 2014, Monteuuis et al., 2019). Altogether, these data support a model in which 
G34R-induced loss of H3.3K36me3 at highly expressed loci (including forebrain master regulator 
genes such as DMRTA2 and ARX) precludes recruitment of the transcriptional repressor 
ZMYND11. We surmise this ultimately results in elevated transcriptional output of such genes 
and helps to sustain the core regulatory network of forebrain identity. Due to the presence of high 
H3.3 incorporation and unique gene sequence features (e.g high intragenic CpG content), we 
speculate that the altered genes may have specific requirements for elongation and/or splicing 
control mechanisms that explain their increased sensitivity to disruption of ZMYND11 
recruitment. 
 
FOXG1 is a competence factor that enables H3.3-G34R driven transformation. 
Surprisingly, despite the transcriptional changes and in vitro phenotype conferred by H3.3-G34R, 
we found that G34R-KO patient cells were still able to form tumours upon xenotransplantation 
(Figure 4H), suggesting that the mutation might be dispensable later in tumorigenesis, once 
widespread genomic disruptions have accumulated. Given the cytostatic effect triggered by H3.3-
G34R in non-forebrain cells, we reasoned that targeting components of the forebrain 
transcriptional network could provide an alternative strategy to limit tumorigenicity of fully 
transformed cells. Interestingly, we observed that the cytostatic effect induced by H3.3-G34R in 
brainstem NSCs is accompanied by activation of the senescence effector CDKN1A/p21 (Figure 
S7A-B), suggesting that cellular senescence is a key protective mechanism that can be overcome 
in forebrain cells.  
 
We therefore focussed on the transcription factor FOXG1, a master regulator of forebrain identity 
and known suppressor of the CDKN1A/p21 locus during brain development (Xuan et al., 1995; 
Seoane et al., 2004; Siegenthaler et al., 2008; Yip et al., 2012; Lujan et al. 2012). Two other aspects 
of FOXG1 biology were relevant. First, FOXG1 is the most upregulated transcription factor gene 
in forebrain versus hindbrain NSC cultures (Figure 1B). Second, FOXG1 is expressed at high 
levels in hemispheric pHGGs independently of the H3.3-G34R mutation (Figure 7A, Figure S7C-
D) and in many adult HGGs (Verginelli et al., 2014; Bulstrode et al. 2017).  
 
Strikingly, ablation of FOXG1 through CRISPR/Cas9-gene editing led to reduced proliferation 
with concomitant p21 upregulation in vitro (Figure 7B-D) and loss of tumour-formation capacity 
of H3.3-G34R patient-derived cells in vivo (Figure 7E-G). In contrast, ablation of FOXG1 in two 
independent H3.3-WT adult hemispheric HGG patient lines with comparable expression levels did 
not induce p21 upregulation nor impaired proliferation, suggesting a stronger dependency of H3.3-
G34R-mutant cells on FOXG1 expression (Figure 7H-L). We therefore propose that FOXG1 acts 
as a regionally-restricted competence factor for H3.3-G34R via establishment of the permissive 





We have demonstrated here the impact of regional NSC identity on the oncogenic effects of H3.3 
oncohistones, and propose that this can explain the unique anatomical distribution of high-grade 
brain tumours in children. Our findings suggest that cell-intrinsic programs associated with 
regional identity of human neural progenitor cells provide unique vulnerabilities to each H3.3 
mutant form. Thus, rather than region-specific microenvironmental influences or systemic 
temporal cues, our data point to the primary importance of the regional identity of the cell-of-
origin in providing a cell intrinsic competence to distinct H3.3 mutations.  
 
The differing cellular responses to H3.3-K27M and H3.3-G34R H3.3 oncohistones clearly 
highlight the importance of studying these mutations in an appropriate spatial-temporal 
developmental context. Understanding of basic disease biology therefore requires modelling in 
human cells with the relevant regional identity with associated transcriptional circuits and 
epigenetic landscapes. Our isogenic series of forebrain and hindbrain self-renewing NSCs now 
provides a human-relevant model to further dissect cellular responses to oncohistone and the 
molecular events underlying initiation of pHGGs. These should complement patient-derived 
models, which are often too corrupted and heterogeneous to retrospectively delineate programs of 
early oncogenesis. At a practical level, these isogenic models can be expanded continuously in 
large numbers, are amenable to genetic manipulation (Bressan et al., 2017) and, similar to adult 
glioma stem cell lines (Pollard et al., 2009), represent a tractable experimental system for chemical 
and genetic screens in search of  new therapeutic targets in pHGGs.  
 
Importantly, working with tissue-derived lines overcomes many of the shortcomings associated 
with ES/iPSC-based models, which are often highly capricious, require lengthy differentiation 
protocols, and result in heterogeneous mixtures of cell types. Noteworthy, in addition to dissecting 
the role of H3.3 oncohistones, the defined origin and identity of our primary foetal NSC lines may 
also facilitate modelling of other paediatric tumors that arise in specific CNS compartments, such 
as medulloblastoma or ependymoma (Gibson et al., 2010: Johnson et al., 2010). In light of this, 
we and others are developing a large collection of human foetal NSC lines across different 
temporal and spatial identities that should enable functional dissection of diverse brain tumour 
drivers, and are being made available to the research community (www.gcgr.org.uk). 
 
Further leveraging on our isogenic models, we were able to garner molecular insights into the 
H3.3-G34R mode of action in the relevant cellular context. Through a combination of mRNA-seq 
profiling and mapping of histone post-translational modifications, we observed that H3.3-G34R 
does not induce pervasive transcriptional or epigenetic changes, but rather operates at already 
highly expressed genes, including key forebrain NSC transcription factors. These findings clearly 
contrast to the reported effects of H3.3-K27M in midline pHGGs and other H3.3 driver mutations 
present in paediatric sarcomas, where the oncohistones appear to cause widespread resetting of 
epigenetic landscapes (Chan et al., 2013; Fang et al., 2016; Lu et al., 2016; Khazaei et al, 2020) 
 
In addition, by exploiting the epitope tagged version of H3.3, we were able to map key protein 
interaction partners of H3.3-G34R in patient-derived cells. Consistent with the idea of alterations 
at specific loci, we identified disrupted binding to ZMYND11 - a putative tumour suppressor that 
is associated with highly expressed genes and operates as a transcriptional co-repressor through 
modulation of elongation and splicing. Interestingly, a previous study has also identified a clonal 
ZMYND11 loss-of-function mutation in hemispheric pHGGs lacking H3.3-G34R, suggesting they 
may operate through a shared pathway (Salloum et al., 2017).  
 
We therefore propose a working model in which  H3.3-G34R does not induce de novo changes in 
transcriptional state, but instead acts to fine tune expression of key transcriptional regulatory genes 
via the release of ZMYND11-based transcriptional repression. Ultimately, this reinforces the pre-
existing progenitor state of the forebrain cell-of-origin, and likely locks cells into a proliferative 
state. Although mechanistically different, these findings add to emerging evidence that mutations 
in histone and chromatin regulatory genes captures susceptible stem cell and progenitor states to 
drive initiation of paediatric tumours (Funato et al., 2014; Lu et al., 2016; Jessa et al., 2019; 
Pathania et al., 2017; Vladoiu et al., 2019, Khazaei et al., 2010). Further studies will now be needed 
to deeply assess the impact of H3.3-G34R on transcriptional elongation and/or alternative splicing, 
and whether its effect can be fully recapitulated by ZMYND11 loss-of-function. Similarly, in-
depth biochemistry and structural analyses will be required to dissect whether ZMYND11 binding 
is directly impaired by the G34R substitution, or rather an indirect consequence of K36me3 loss 
on the mutant histone. 
 
Finally, our data suggests that targeting core lineage-affiliated transcription factors, such as 
FOXG1, might be an attractive approach for therapeutic development. While the design of 
conventional small molecule inhibitors that target transcription factors presents considerable 
challenges, there has been significant progress in targeting these with innovative strategies, 
including modulation of auto-inhibition, proteolysis targeting chimaeras (PROTACs), and 
cysteine reactive inhibitors (Bushweller, 2019). Increased understanding of transcription factor 
biochemical functions may further reveal critical post-translational modifications and/or co-factors 
that could be disrupted for therapeutic purposes. We also note the shared dependencies on FOXG1 
for both paediatric H3.3-G34R-mutant and adult HGGs (Bulstrode et al., 2017; Verginelli et al., 
2013). It appears that, despite being driven by divergent genetic disruptions (Jones et al., 2017), 
both adult and paediatric diseases may converge and harness elevated expression of a forebrain 
neural stem/progenitor cell transcriptional network. It will be interesting in future studies to 
explore the role of other key components of the forebrain regulatory circuit and to dissect in detail 
how these are established and impacted by  H3.3-G34R. 
  
In conclusion, our data indicate that the regional identity of human NSCs is critically important 
for the oncogenic responses to distinct H3.3 mutant forms. Further work will now be needed to 
fully dissect why regional progenitor states are differentially sensitised to each H3.3 mutation, and 
whether mechanisms sustaining forebrain and hindbrain identities could be targeted for therapeutic 
purposes. Our hope is that this identification of the crucial target cell populations, and underlying 




Limitations of the study 
A current major limitation in studies of pHGG is the difficulty in obtaining tumour specimens and 
patient cell lines due to the challenging anatomical location and rarity of the disease. Although our 
findings with the patient-derived pGBM002 cell line are supported by the engineered foetal NSC 
models and rescue experiments, it will be important to further validate key target genes and the 
requirement of the mutant histone in late tumorigenesis as novel models emerge and other patient 
lines became available to the community.  Similarly, while we clearly demonstrate the importance 
of the forebrain developmental context, it will be important to determine in future studies whether 
dorsal-ventral regional programs or progenitor subtype identities provide further layers of 
competence to H3.3-G34R. Mechanistically, deeper analyses of the total RNA expression will be 
required to explore the impact of H3.3-G34R on elongation and splicing control, and whether 
ZMYND11 inhibition recapitulates the effect of H3.3-G34R. Finally, in exploring the role of 
FOXG1, we have been unable to isolate expandable cells following conventional knockout and 
overexpression approaches in forebrain and hindbrain NSC cultures, respectively. Modulation of 
FOXG1 expression using CRISPRa/CRISPRi might provide an alternative experimental strategy 
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Figure 1 | Core transcriptional signatures of regional identity are captured in human 
primary foetal NSC cultures and define pHGG subtypes. See also Figure S2 and Table S1 
(A) Overview of the approach used for derivation of human foetal region-specific NSC cultures. 
Three foetal specimens aged 13.5, 15.0 and 19.3 WGA (GCGR-NS13, GCGR-NS15 and GCGR-
NS19, respectively) were used. Established lines were profiled after 5-10 passages in culture. Total 
RNA collected from the freshly dissected tissue segments was used as a reference control. WGA, 
weeks of gestational age.  
(B) Heatmap showing expression of forebrain- and hindbrain-specific genes in the freshly 
dissected primary tissue and matched NSC cultures. Region-specific expression signatures were 
generated for reference tissue samples and NSC cultures separately, and the intersection of the two 
sets was taken (see Methods). Forebrain- and hindbrain-specific gene symbols are shown in blue 
and green lettering, respectively. 
(C) Principal component analysis (PCA) of primary foetal tissue samples and NSC lines based on 
500 genes with the highest variance across all samples. 
(D) Gene ontology analysis (domain biological process) of PCA loadings for principal component 
1 (PC1) and principal component 2 (PC2). PC1, which segregates NSC lines from primary tissue 
samples, is enriched in neuronal differentiation terms. In contrast, PC2 separates samples 
according to anatomical region of origin and is enriched in regionalisation and antero-posterior 
specification terms. 
(E) PCA of primary patient pHGG tumour samples (GEO accessions: GSE34824, GSE36245, 
GSE19578). Left panel: PCA based on tumour-derived G34- and K27-mutant signatures. Right 
panel: PCA based on forebrain- and hindbrain-specific gene sets extracted from the reference 
foetal tissue and NSC cultures in panel (A).  
(F) Consensus clustering of patient pHGG tumour samples using G34/K27 (left) and 
forebrain/hindbrain (right) gene sets. Heatmaps are clustered using hierarchical clustering with 
Euclidean distance and average linkage criteria into 3 predominant groups corresponding to 
tumour H3.3 status (WT, K27M, and G34R/V). 
(G) Boxplots of ssGSEA enrichment scores for K27 and G34 signatures among the established 
region-specific foetal NSC lines. Cell line numbering corresponds to the anatomical regions in 
panel (a). Boxes show median, first and third quartile, and whiskers extend to 1.5× the interquartile 
range (IQR). 
(H) Boxplots of ssGSEA enrichment scores comparing forebrain and hindbrain signatures 
extracted from the primary foetal tissue datasets among pHGG H3.3 subtypes. Boxes show 
median, first and third quartile, and whiskers extend to 1.5× the IQR.  
(I) Boxplots of ssGSEA enrichment scores comparing the gene sets extracted from the established 
NSC lines from each position among pHGG H3.3 subtypes. Boxes show median, first and third 
quartile, and whiskers extend to 1.5× the IQR. 
 
Figure 2 | H3.3-K27M preferentially increases growth of brainstem NSCs.  
(A) Immunocytochemistry analysis confirming comparable levels of V5-tagged WT and K27M 
H3.3 expression in the three regional NSC lines. Global loss of H3K27me3 is observed in H3.3-
K27M-expressing cells. Representative images of the lines derived from specimen GCGR-NS13 
are shown. Scale bar: 20 μm. 
(B) Quantification of EdU incorporation in the regional NSC lines carrying H3.3-WT and -K27M 
constructs. Plots depict mean ± standard deviation percentage EdU-positive cells in the indicated 
cell lines. Student’s t-test p-values are shown. n.s, non-significant.  n = 3 independent experiments 
performed with 3-4 technical replicas each. 
(C) Quantification of colony formation activity of regional NSC lines carrying H3.3-WT and -
K27M constructs. Individual dots represent the absolute colony counting per well. Horizontal lines 
represent mean ± standard deviation. Student’s t-test p-values are shown. 
(D) Quantification of SA-βgal positive cells in the regional NSC lines carrying H3.3-WT and -
K27M constructs. Plots depict mean ± standard deviation percentage of positive cells. Student’s t-




Figure 3 | H3.3-G34R triggers differential phenotypic responses in forebrain and brainstem 
NSCs. See also Figure S3 
(A) Immunoblot analysis confirming comparable expression of V5-tagged H3.3 in the NSC lines 
carrying WT and G34R H3.3 constructs. Representative blot images from GCGR-NS13 lines are 
shown. Expression of forebrain marker FOXG1 is shown for comparison purposes.  
(B) Quantification of EdU incorporation in the regional NSC lines expressing H3.3-WT and -
G34R. Plots depict mean ± standard deviation percentage of positive cells in the indicated cell 
lines. Student’s t-test p-values are shown. n.s, non-significant. n = 3 independent experiments 
performed with 3-4 technical replicas each. 
(C) Quantification of colony formation activity of regional NSC lines expressing H3.3-WT and -
G34R. Individual dots represent the absolute colony counting per well. Horizontal lines represent 
mean ± standard deviation. Student’s t-test p-values are shown. 
(D) Quantification of apoptotic, active Caspase3-positive cells in the regional NSC lines carrying 
H3.3-WT and -G34R constructs. Plots depict mean ± standard deviation percentage of positive 
cells. p-value by Student’s t-test. n = 3 independent experiments performed with 3-4 technical 
replicas each. 
(E) Quantification of SA-βgal positive cells in the regional NSC lines expressing H3.3-WT and -
G34R. Plots depict mean ± standard deviation percentage of positive cells. Student’s t-test p-values 
are shown. n.s, non-significant. Representative images of indicated lines derived from specimen 
GCGR-NS13 are shown. Scale bar: 100 μm. n = 3 independent experiments performed with 3-4 
technical replicas each. 
(F) Immunoblot analysis confirming loss of P53 protein, and ectopic expression of V5-tagged 
H3.3 and PDGFRa in the engineered GCGR-NS13 Neocortex and Brainstem PP5W and PP5G 
cells. Protein lysates from non-edited cells were used as controls. 
(G) Phenotypic in vitro characterisation of GCGR-NS13 neocortex and brainstem PP5W and 
PP5G cells. Plots show quantification of EdU incorporation (n =3), colony formation (n = 12) and 
SA-βgal assays (n =3).  
(H) Kaplan-Meier curve showing survival data of immunocompromised mice transplanted with 
GCGR-NS13 neocortical PP5W and PP5G cells. 
(I) Analysis of brain tissue from mice transplanted with GFP-labelled neocortical PP5W and PP5G 
cells. Left panel shows microscopic views of freshly dissected brains from each group. Right panel 
shows immunohistochemistry images (coronal sections) of the corresponding specimens. The 
transplanted human cells are stained with a GFP antibody. Scale bar: 1.5mm 
  
Figure 4 | Genetic ablation of mutant H3F3A allele in patient-derived NSC line reveals 
forebrain neuroprogenitor genes as downstream targets of H3.3-G34R. See also Figure S4 
(A) Schematics of the strategy used to inactivate the H3F3A G34R allele through CRISPR/Cas9 
gene editing. The G-to-A nucleotide substitution that results in the G34R mutation occurs 5’ 
adjacent to a GGG stretch (red) that serendipitously serves as a protospacer adjacent motif (PAM) 
for Cas9 recognition. As mismatches within the PAM-proximal region preclude Cas9 cleavage, 
this allows the design of a sgRNA (blue sequence) that specifically cuts the G34R allele. Dashed 
rectangles show codons for residues Gly34 (WT allele) or Arg34 (G34R allele).  
(B) Genotyping result of the parental and a representative G34R-KO clone. WT allele (encoding 
Gly34) remains intact, while G34R allele harbours a frameshifting 1 bp deletion at the predicted 
sgRNA cut site (yellow arrow). 
(C) Immunocytochemistry analysis confirms loss of H3.3-G34R protein expression in the G34R-
KO cells.  Parental line and representative G34R-KO clone are shown. Scale bar: 50 μm. 
(D) Confluence analysis indicates impaired in vitro growth of G34R-KO clones. Parental cells 
were used as reference. **** adjusted p < 0.0001 by one-way ANOVA followed by Dunnett’s test 
(each G34R-KO clone vs parental cells at 240 h elapsed). Plot shows results of one representative 
experiment performed with 4 technical replicas. 
(E) Quantification of EdU incorporation in pGBM002 parental and G34R-KO clonal lines. Plot 
depicts mean ± standard deviation. *p < 0.05, ***p<0.001 by One-way ANOVA followed by 
Dunnett’s multiple comparisons test (mean of each clone vs parental). n = 4 independent 
experiments performed with 3-4 technical replicas each. 
(F) Quantification of colony formation activity of parental pGBM002 and G34R-KO clonal lines. 
Individual dots represent the absolute colony counting per well. Horizontal lines represent mean ± 
standard deviation. ****p<0.0001 by One-way ANOVA followed by Dunnett’s multiple 
comparisons test (mean of each clone vs parental).  
(G) Quantification of SA-βgal positive cells in parental pGBM002 and G34R-KO clonal lines. 
Plot depicts mean ± standard deviation. *p < 0.05, ***p < 0.001, ****p < 0.0001 by One-way 
ANOVA followed by Dunnett’s multiple comparisons test (mean of each clone vs parental). n = 3 
independent experiments performed with 3-4 technical replicas each. 
(H) Results of xenotransplantation experiments with parental pGBM002 and G34R-KO clones. 
Left panel shows representative images of in vivo bioluminescence imaging of intracranial tumours 
formed by parental and a G34R-KO clonal line. Kaplan-Meier curve (right) shows survival data 
of mice transplanted with the parental cells (blue line) and each G34R-KO clone (grey lines). 
(I) PCA plot confirms consistent transcriptional profile changes between parental pGBM002 (three 
independent passages) and three G34R-KO clonal lines (one passage each). The 500 genes with 
highest variance across samples were used for the PCA. 
(J) Volcano plot showing differentially expressed genes between parental and G34R-KO clonal 
lines. Genes downregulated in the G34R-KO clones are shown in blue. Upregulated genes shown 
in red. Vertical dotted lines mark absolute log2 fold change > 1. Horizontal lines - false discovery 
rate (FDR) < 0.05. 
(K) Gene ontology (GO) analysis of downregulated and upregulated genes (FDR < 0.05) in G34R-
KO clones for GO domain Biological Process. 
(L) Heatmap showing expression of genes within the ‘Forebrain Development’ GO term found to 
be downregulated in G34R-KO clones. 
(M) Boxplot showing expression levels of the indicated forebrain progenitor-related genes in 
hemispheric pHGG patient tumour samples. Data was retrieved from an integrated transcriptomic 
study of pHGGs available on the paediatric cBioPortal – see methods). Only specimens whose 
hemispheric location and H3F3A mutation status could be ascertained were included. * p < 0.05, 
** < 0.01, *** < 0.001 and **** < 0.0001 by Student’s t test (WT vs G34R/V groups).  
  
Figure 5 | Genome-wide profiling of H3.3 and associated histone H3 marks in isogenic 
patient-derived H3.3-G34R pHGG cells. See also Figures S5-S6. 
(A)  Heatmaps and metagene plots showing H3.3-G34R, H3K4me3, H3K36me3 and H3K27me3 
ChIP-seq signal at all annotated human genes (hg38 knownGene) in parental and G34R-KO 
pGBM002 cells. Genes within each heatmap are ranked by abundance of the H3.3-G34R or 
indicated histone mark in the parental cells.  
(B) Box plots depicting abundance of each indicated histone H3 modification (log2 RPKM) at 
genes grouped into quantiles of G34R abundance in parental pGBM002 cells. Quantiles 1 and 4 
include, respectively, genes with the lowest and highest H3.3-G34R coverage levels. Boxes show 
median, first and third quartile, and whiskers extend to 1.5× the IQR (n=2 replicates for each 
histone mark). 
(C) Box plots depicting abundance of H3.3-G34R (log2 RPKM)  at genes grouped into coverage 
quantiles of the indicated histone mark. Quantiles 1 and 4 include genes with the lowest and highest 
levels of each mark, respectively (n=2).  
(D) Box plots depicting total mRNA expression levels (log2 RPKM) per H3.3-G34R quantile in 
parental and G34R-KO cells. Quantiles 1 and 4 include, respectively, genes with the lowest and 
highest H3.3-G34R coverage levels (n=3). 
(E) Box plot depicting H3.3-G34R coverage (log2 RPKM) in parental cells per mRNA expression 
quantiles defined in parental (left) and G34R-KO (right) cells. Quantiles 1 and 4 include, 
respectively, genes with the lowest and highest absolute mRNA expression levels (n=2). 
(F) Scatter plot showing V5-H3.3 coverage per 50kb genomic bins in G34R-KO cells rescued with 
V5-tagged H3.3 WT - and G34R construct. Density reported as log2 density. SCC 0.91, p-value < 
0.001. 
(G) Tracks of V5-WT and V5-G34R H3.3 subtracted and normalised coverage (RPM) over 
chromosome 8 (upper), and selected region (lower, Chr8 p22-21.2). 
(H) Log2 fold change (Parental vs G34R-KO cells) in H3K4me3, H3K36me3, and H3K27me3 
coverage (RPKM) within each H3.3-G34R quartile. 
(I) Venn diagrams and metagene plots of common and exclusive peaks in pGBM002 Parental and 
G34R-KO lines (Left to right – Parental, Common, and G34R-KO peaks). Peaks were selected as 
promoter specific (+/- 2kb from TSS) for H3K4me3 and H3K27me3 histone marks, and gene body 
associated (between TSS and TES) for H3K36me3. 
(J) RNA-seq mRNA log2 fold change (Parental Vs. G34R-KO) of genes associated with peaks 
defined in panel (I).  
 
Figure 6 | G34R mutation precludes binding to the transcriptional repressor ZMYND11. See 
also Table S2 
(A) Immunoblotting of anti-V5-immunoprecipitated H3.3-WT and -G34R ectopically expressed 
in patient derived G34R-KO pGBM002 cells.  Endogenous (lower band) and V5-tagged ectopic 
H3.3 (upper band) are indicated. Loss of K36me3 is specific to ectopic H3.3-G34R. Non-
transfected G34R-KO cells were used as controls (first and fourth lane). 
(B) Metagene plot (left) and boxplot (right) showing H3.3-G34R coverage (subtracted RPM, and 
log2 RPM respectively) for Expressed (n=13695), Upregulated (n=842), Downregulated - all 
(n=475), and Downregulated – forebrain associated (n=44) genes. Expressed genes were defined 
as those with mean RPKM > 1 within pGBM002 parental samples (see methods). All other gene 
sets were defined based on differential expression between G34R-KO and parental cells (Fig.4I-
L). *** p < 0.005 and ****p < 0.0001 for pair-wise comparisons against the ‘all expressed’ group. 
See STAR methods for details on the statistical test. 
(C) Genomic track showing H3.3-G34R enrichment and mRNA expression over transcriptional 
factor genes DMRTA2 (left) and DLX1 (right) in parental and G34R-KO pGBM002 cells. 
DMRTA2 and DLX2 are shown as representative forebrain-related downregulated and unchanged 
genes in G34R-KO cells. 
(D) Volcano plot showing differentially bound partners of ectopically expressed WT and G34R 
mutant V5-tagged H3.3 identified through IP-MS. The x-axis shows the fold-change value 
(G34R/WT) and y axis shows p-value (−log10 scale) for statistical significance. Absolute 3-fold 
change and p-value 0.1 (vertical and horizontal dashed lines, respectively) were used as the 
threshold cutoff. Blue and green dots depict partners with increased and decreased binding to H3.3-
G34R, respectively. 
(E) Immunoblotting analysis for ZMYND11 and HIRA co-immunoprecipated with ectopic V5-
H3.3 (WT and G34R) in G34R-KO pGBM002 patient cells, and engineered neocortex NSC line 
(H3.3 overexpression alone, and in combination with p53-knockout and PDGFRA overexpression 
- PP5W/PP5G model). 
(F)  Boxplots showing quantification of sequence length, GC content, CpG content, and CpG 
island overlap for full transcript, exonic and intronic ranges in the defined gene sets. Only 
expressed genes were included in the analyses - see methods for details. All expressed (n=13695), 
Downregulated - all (n=475) and Downregulated – forebrain associated (n=44). ** p < 0.05, *** 
p < 0.005 and ****p < 0.0001 for pair-wise comparisons against the ‘all expressed’ group. See 
STAR methods for details on the statistical test. 
 
Figure 7 | Genetic disruption of FOXG1 impairs tumourigenesis of patient-derived G34R-
mutant NSC cells. See also Figure S7 
(A) Expression levels of FOXG1 mRNA in patient pHGG primary tumours. Data was retrieved 
from the integrated pHGG transcriptomic dataset available on the paediatric cBioPortal – see 
methods.  N.s, non-significant and **** p < 0.0001 by one-way ANOVA followed Tukey’s 
multiple comparisons test.  
(B) Immunoblot analysis confirming loss of FOXG1 protein in the pGBM002 knockout clonal 
line. Blot against GAPDH was used as internal control. 
(C) Quantification of EdU incorporation (24h pulse) and colony formation activity in parental and 
FOXG1-knockout pGBM002 cells. Plot depicts mean ± standard deviation. **** p<0.0001 by 
Student’s t test. n = 4 independent experiments performed with 3-4 technical replicas each. 
(D) Immunoblot analysis showing increased p21 expression in the FOXG1-knockout clonal line 
following exposure to TGFβ in the culture media for 96 h. TGFβ treatment was used to stabilise 
p21 protein expression as previously described (Seoane et al., 2014). 
(E) In vivo bioluminescence imaging of mice transplanted with parental and FOXG1-knockout 
pGBM002 cells labelled with a constitutively expressed GFP-Luciferase reporter. Plot depicts 
absolute luminescence values (photons per second) per mouse at the indicated time points. 
Representative images were collected at 150 days following transplantation. 
(F) Representative immunohistochemistry images of the brain tissue from immunocompromised 
mice transplanted with parental and FOXG1-knockout pGBM002 cells.  
(G) Kaplan-Meier curve showing survival data of mice transplanted with parental and FOXG1-
KO pGBM002 cells. Mice in the FOXG1-KO group were sacrificed after 400 days and no signs 
of tumour formation was observed. Scale bar: 1.5mm 
(H) RT-qPCR-based relative quantification of FOXG1 expression levels in H3.3-G34R mutant 
pHGG (pGBM002) and H3.3-WT adult HGG (aGBM7 and aGBM313). Primary foetal neocortex 
and brainstem NSC lines (specimen GCGR-NS19) were used for comparison. n = 2-3 independent 
passages of each cell line. 
(I) Western blotting analysis showing protein expression of FOXG1 and p21 in parental and 
respective FOXG-KO lines. H3.3 status of each line is shown in the round rectangles below the 
panel.  
(J) RT-qPCR results showing relative expression levels of CDKN1A in FOXG1-KO cells. Parental 
cells were used as normaliser for each pairwise comparison. **p < 0.01 by Student’s t-test. n.s, 
non significant. n = 3 independent passages of each cell line. 
(K) Quantification of EdU incorporation (2h pulse) in FOXG1-KO and respective parental lines. 
Plots depict mean ± standard deviation. *** p<0.001 by Student’s t-test. n.s, non significant. n = 
3-4 independent experiments performed with 3 technical replicas each. 
(L) Quantification of SA-β-gal positive cells in FOXG1-KO and respective parental lines. Plots 
depict mean ± standard deviation. *p < 0.05 by Student’s t-test. n.s, non significant. n = 4 





Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Steven Pollard (steven.pollard@ed.ac.uk ). 
 
Materials availability 
Stable reagents generated in this study are available from the Lead Contact. Unedited human foetal 
human NSC lines must be requested from the Glioma Cellular Genetics Resource (gcgr.org.uk) 
and a Materials Transfer Agreement completed. 
 
Data and Code Availability 
The RNA-seq and ChIP-seq datasets reported in this paper are deposited in Gene Expression 
Omnibus (GEO) with the following accession codes: GSE163044 and GSE163185. Proteomics 
data is available at ProteomeXchange with identifier PXD021270. 
 
Plasmids 
H3.3 expression vectors were generated through engineering a Gateway destination vector 
containing a CAG promoter-driven transcriptional unit and a PGK-Hygromycin selection cassette 
flanked by PiggyBac transposon-specific inverted repeats. The sequences encoding C-terminal 
V5-tagged WT,  K27M- and G34R-mutant H3.3 were generated by commercial DNA synthesis 
(Life Technologies). These were flanked by AttL recombination sites and directly inserted into the 
destination vector via Gateway LR cloning. PDGFRA coding sequence was PCR-amplified from 
human cDNA and cloned into a similar Gateway-compatible vector containing a CAG-Blasticidin 
resistance cassette and PiggyBac transposon flanking sequences. The PiggyBac Luciferase-2A-
GFP expression vector was generated through LR Gateway cloning of an existing entry clone 
(Bressan et al. 2017).  Human TP53 and FOXG1 CRISPR sgRNAs and targeting vectors were 
previously described (Bressan et al. 2017; Bulstrode et al. 2017). Cas9-encoding plasmid was 
obtained from Addgene. PBase transposase plasmid was a gift from Austin Smith (University of 
Cambridge). 
 
Human tissue collection and derivation of NSC cultures 
Fresh human foetal CNS tissue was obtained following elective termination of pregnancy at 13.5, 
15.0 and 19.3 weeks of gestational age (WGA) (specimens GCGR-NS13, GCGR-NS15 and 
GCGR-NS19, respectively) with no evidence of developmental abnormalities. Informed consent 
was obtained in writing, and all procedures received ethical approval (South East Scotland 
Research Ethics Committee, REC reference 08/S1101/1). The regions of interest (Figure 1a) were 
dissected under a stereoscope with a pair of fine forceps in ice-cold PBS. In the case of the 
brainstem, an incision was made at the midbrain-hindbrain boundary and medullary hindbrain-
spinal cord boundary. Following dissection of the cerebellum, an incision was made at the level of 
the rhombic lip, thereby dividing the segment into anterior and posterior brainstem. In the case of 
the spinal cord, the proximal segment (approx. 3-5 mm adjacent to the medulla) was collected. 
Following dissection, each tissue segment was split in two, with the first half (tissue reference) 
being directly lysed in Qiagen RLT plus buffer for subsequent RNA collection. The second half 
was mechanically dissociated with a pair of forceps followed by gentle pipetting. The resultant 
cell suspensions were centrifuged (400g for 3min), resuspended in NSC culture medium (see 
below) and plated onto T25 tissue culture flasks. Within 24h, morphologically diverse cells 
attached to the culture plastic. To reduce the amount of debris and cell death, culture media was 
refreshed at 24h and then every seven days. Within 1-2 weeks, clusters of adherent cells 
morphologically resembling radial glia-like NSCs emerged. After passaging, these rapidly adopted 
a more uniform morphology and stable proliferation rates. Cell death was minimal and most 
cultures could be maintained for >10 passages without signs of proliferative arrest or spontaneous 
differentiation. Expandable neocortex, striatum and brainstem-derived cultures were consistently 
established from all three specimens, while cultures from other regions did not expand long-term 
in some cases. RNA was collected from two independent passages of each established line for 
mRNA profiling (Fig.1). The H3.3-G34R-mutant pGBM002 cell line was derived from a biopsy 
of a hemispheric tumour in a 15-year-old patient and kindly provided by Angel M. Carcaboso 
(Institut de Recerca Sant Joan de Deu, Spain) 
 
Cell line engineering 
Human foetal NSCs were engineered at 5-7 passages after establishment. Transfections were 
performed using the Amaxa 4D nucleofector system as previously described (Bressan et al. 2017). 
For H3.3 expression, 200ng of PiggyBac donor plasmid (WT, K27M- or G34R-H3.3) was co-
transfected with 400ng of PBase transposase plasmid. For combined PDGFRA expression and 
TP53 knockout, the PiggyBAC PDGFRA donor vector (200ng), TP53 sgRNAs (200ng each), 
TP53 targeting vector (200ng) and Cas9 encoding plasmid (400ng) were added to the reaction. 
Following recovery, cells were selected for stable integration of PiggyBac donor vectors and TP53 
targeting vector using sequential treatment with 50μg/ml hygromycin (H3.3), 5 μg/ml blasticidin 
(PDGFRA) and 100 ng/ml puromycin (TP53 knockout). The resulting resistant cell population 
was expanded for 3-4 passages before functional and transcriptional profiling. For knockout of the 
H3.3-G34R allele, a customised allele-specific crRNA was hybridised with a universal tracrRNA 
(both from Integrated DNA Technologies) and complexed with recombinant Cas9 protein as 
previously described (Dewari et al. 2018). The ribonucleoprotein complex was delivered into 
pGBM002 cells using the Amaxa-4D nucleofector system (Lonza, SG solution, program EN137). 
Following recovery, cells were plated at low density (approx. 10 cells/cm2) and individual colonies 
manually picked after three weeks. Clones were expanded and the H3F3A locus amplified by PCR 
and sequenced by Sanger sequencing. FOXG1 knockout was performed through CRISPR/Cas9-
mediated gene targeting using previously validated sgRNA and targeting vectors (Bulstrode et al. 
2017). Drug resistant colonies were manually picked and screened by PCR-based genotyping and 
Sanger sequencing as previously described (Bressan et al. 2017). For xenotransplantation 
experiments, engineered lines were co-transfected with the Luciferase-2A-GFP donor (200ng) and 
PBase transposase (400ng), and GFP-positive cells enriched by FACS. 
 
Cell line maintenance  
Established lines and engineered derivatives were propagated under identical culture conditions in 
serum-free basal medium supplemented with N2 and B27, Laminin-1 (1 μg/ml) and growth factors 
EGF and basic FGF (10 ng/ml each) as previously described (Bressan et al. 2017). Medium was 
exchanged twice per week. Upon confluence, cells were dissociated with Accutase solution and 
split typically 1:3 to 1:5.  
 
Immunocytochemistry 
Cells were fixed in 4% paraformaldehyde (PFA), permeabilized in 0.1% Triton X-100 and blocked 
in 0.1% bovine serum albumin plus 3% goat serum PBS solution. Samples were incubated 
overnight at 4°C with primary antibodies, washed in 0.3% Triton X-100 and reincubated with 
appropriate fluorophore-conjugated secondary antibodies (1:1000) and 4′,6-diamidino-2-
phenylindole (DAPI) at room temperature for one hour. Immunopositive cells were quantified 
from a total ∼5000 cells in a minimum of ten random fields. Total cell number was determined by 
DAPI nuclear staining. The following primary antibodies were used: active Caspase3 (1:500), 
Foxg1 (1:10), H3K27me3 (1:1000), H3.3 (1:200), H3.3-G34R (1:1000), Nestin (1:500), Sox2 
(1:50), V5-tag (1:1000) and Vimentin (1:50). 
 
Western immunoblotting 
Whole cell protein lysates were prepared in RIPA buffer (25 mM Tris-HCl. pH7.6, 150 mM NaCl, 
1% NP-40, 1% Sodium Deoxycholate, 0.1% SDS) containing 1x protease inhibitor cocktail. 
Briefly, the cell pellets were resuspended in 100ul of RIPA buffer, incubated 5 minutes on ice and 
centrifuged at 4°C (10 minutes 15,000g) to remove cell debris. Histone extracts were prepared as 
previously described (Shechter et al., 2007).  Following protein quantification with the BCA 
method, extracts were separated on 4–12% Bis-Tris gels and transferred to nitrocellulose 
membranes using the Mini Trans-Blot Cell system (Biorad). Membranes were incubated overnight 
with primary antibodies diluted in 5% milk TBS-Tween solution followed by incubation with 
horseradish peroxidase-conjugated secondary antibodies (1:5000). The following primary 
antibodies were used: Foxg1 (1:50), GAPDH (1:1000), p53 (1:500), V5 tag (1:1000), total H3 
(1:2000), H3.3 (1:1000), PDGFRA (1:1000), p21 (1:1000), ATRX (1:100), Zmynd11 (1:500), 
HIRA (1:1000), H3K9-K14-K18-K27ac (1:1000), H3K27ac (1:1000), H3K4me2 (1:1000), 
H3K4me3 (1:1000), H3K9me3 (1:1000), H3K27me2 (1:1000), H3K27me3 (1:1000), H3K36me2 
(1:5000) and H3K36me3 (1:1000).  
 
EdU-incorporation assay 
Cells were plated at 5,000 cells/cm2 in 48-well plates for 72h, followed by incubation with 10μM 
EdU for, unless otherwise stated, 24h. EdU staining was carried out using the Click-iT EdU assay 
kit according to manufacturer’s instructions. EdU-positive cells were quantified from a total 
∼5000 cells in a minimum of ten random fields. Total cell number was determined by DAPI 
nuclear staining.  
 
Colony formation and confluence analyses  
For colony formation assays, cells were plated at 15 cells/cm2 in 6-well plates, and colony 
counting performed manually 21 days after plating. For confluence analysis, cells were plated at 
5,000 cells/cm2 in 24-well plates and imaged on the Incucyte Zoom live cell imaging system (Essen 
Bioscience) until confluence was reached. Growth curves were generated with the built-in Incucyte 
Zoom software.  
 
SA-βGal staining 
Cells were plated at 5,000 cells/cm2 in 48-well plates for 96h, followed by fixation with solution 
containing 2% formaldehyde and 0.2% glutaraldehyde for 5 min. Staining was performed 
overnight with the Senescence Cells Histochemical Staining kit according to manufacturer’s 
instructions. Plates were imaged using phase contrast microscopy and positive cells manually 
quantified from a total ∼2000 cells in a minimum of ten random fields. 
 
Xenotransplantation 
Xenotransplantation experiments were performed as previously described (Pollard et al. 2009). 
Briefly, cells were detached with Accutase, spun down and diluted at 100,000 cells per microliter 
in sterile PBS. Two microliters of the cell solution were injected stereotactically into the striatum 
of 6- to 8-week-old NSG mice under general anaesthesia. For luciferase imaging experiments, D-
luciferin (50mg/kg dose) was injected intraperitoneally and animals imaged 20 minutes after with 
the PerkinElmer IVIS Lumina LT Series III (PerkinElmer) instrument. Animals were observed 
regularly until they became moribund or showed severe neurological symptoms, at which point 
they were sacrificed and the presence of intracranial tumours confirmed under a fluorescent 
stereoscope. All procedures were carried out in a designated facility under licenses issued and 
approved by the UK Government Home Office 
 
Histological analysis 
Brain tissue was collected and fixed in 4% PFA solution overnight. Coronal sections (50μm) were 
processed with the Vibratome instrument (VT1000S, Leica) and blocked in PBS containing 0.2% 
Triton X-100 and 10% goat serum for 1h at room temperature. Sections were incubated overnight 
at 4°C with an anti-GFP antibody (1:500) followed by incubation with fluorophore-conjugated 
secondary antibody (1:1,000; Invitrogen) and DAPI for 1h at room temperature. Slides were 
mounted using FluorSave reagent and examined with a confocal microscope (TCS SP8, Leica).  
 
RT-qPCR 
Total RNA was extracted using the RNeasy Plus Mini Kit following manufacturer’s instructions 
and cDNA generated with random hexamers and SuperScript III Reverse Transcriptase. 
Quantitative PCR was performed using universal TaqMan PCR master mix and commercial 
Taqman gene expression assays. 
 
RNA-sequencing 
Total RNA was extracted using the RNeasy Plus Mini Kit following manufacturer’s instructions. 
RNA quality was confirmed using the Bioanalyzer RNA 600 Nano kit (Agilent). Libraries were 
generated with 200ng of RNA input using the KAPA mRNA HyperPrep kit and KAPA SeqCap 
adapters. Fragmentation was carried out at 94°C for 6 minutes and libraries amplified for 12 cycles. 
Pooling ratios for multiplex library sequencing was calculated according to individual library 
concentrations and size distributions assessed with the Qubit dsDNA high-sensitivity and Agilent 
Bioanalyzer DNA 1000 assays, respectively. Pooled libraries were diluted and processed for 
sequencing using the Illumina HiSeq 2500 platform. 
 
Chromatin immunoprecipitation followed by next-generation sequencing (ChIP-seq) 
Cells were fixed in culture media containing 1% formaldehyde at room temperature for 10 minutes. 
The crosslinking reaction was quenched by addition of glycine to a final concentration of 0.125M 
to the fixation solution for 5 minutes at room temperature. Fixed cells were detached through 
mechanical scrapping, pelleted by centrifugation and washed twice with ice-cold PBS. The cell 
pellet was resuspended in LB1 buffer (50 mm HEPES, 140mm NaCl, 1 mm EDTA, 10% glycerol, 
0.5% NP40 and 0.25% Triton X100) followed by incubation at 4C for 10 minutes. A nuclear 
fraction was subsequently obtained through centrifugation and resuspended in LB2 buffer (10 mM 
Tris ph8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA). Following centrifugation, the pelleted 
nuclei were lysed in ChIP sonication buffer (50mM HEPES, 140mM NaCl, 1mM EDTA, 1mM 
EGTA, 1% Triton X-100, 0.1% Sodium Deoxycholate, 0.3% SDS) and sonicated in a Covaris 
M220 equipment to yield 200–500 bp DNA fragments. Protease inhibitor cocktail was added to 
all LB buffers. ChIP-grade antibodies (10ug per reaction) were coupled to Dynabeads Protein G 
(50ul per reaction) for 6h at 4°C, and added to sonicated chromatin for 16h under gentle rotation 
at 4°C. Beads were precipitated using a magnetic rack and washed five times with wash buffer 
(50mM HEPES, 500mM NaCl, 1mM EDTA, 1% NP40 and 0.7% sodium deoxycholate). 
Immunoprecipitated DNA was eluted in 50mM Tris-HCl pH8.0, 10mM EDTA, 1% SDS for 60 
minutes at 65ºC. Following an overnight incubation at 65ºC for crosslinking reversal, samples 
were treated with RnaseA (0.2 mg/ml) and proteinase K (0.2 mg/ml), and DNA fragments 
subsequently purified with MinElute PCR purification kit. Purified DNA was quantified using a 
Qubit fluorimeter, and 20 ng was used to generate ChIP-seq libraries using NEBNext Ultra II DNA 
Library Kit and NEBNextdual index primer sets for Illumina. Library DNA was quantified using 
the Qubit, and size distributions were ascertained on a Tapestation (Agilent) using the D1000 
ScreenTape assay. Libraries were pooled at equimolar ratio multiplex library sequencing using the 
concentration and size distribution values of the individual libraries. The library pool was diluted 




Cells were detached with accutase solution, washed in PBS and frozen at -80C. Typically two 
confluent 15cm dishes were used per line or replica. Cell pellets were thawed and resuspended  in 
1ml of lysis buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5% NP-40, 5% glycerol, 
1 mM DTT, 2 mM MgCl2 1mM NaF, 2 mM ortovanadate and protease inhibitor 
cocktail. Following resuspension, benzonase nuclease (150 units/ml) was added and samples 
incubated for 30 min at 4C in a rotating shaker. Lysates were centrifuged at 20,000g for 10 min at 
4C and supernatants collected for protein quantification using the BCA method. Anti-V5 tag 
magnetic beads were added to the lysates (50ul of beads to 1mg of protein), and samples incubated 
in a rotator for 4 hours  at 4C. Beads were subsequently precipitated using a magnetic rack, and 
washed three times with the lysis buffer without NP-40. For western blotting-based experiments, 
beads were subsequently resuspended in 50ul of LDS buffer, incubated at 95C for 10min, and 
separated on 4–12% Bis-Tris gels as described above. Input controls consisted of 5ul of the lysates 
prior addition of anti-V5-tag beads. Alternatively, washed beads were flash frozen in liquid 
nitrogen and stored at -80C until further processing for mass-spectrometry as below.  
 
Mass-spectrometry  
After washing, beads were incubated for 30 minutes at 27C in 2M urea, 75 mM Tris pH8.5, 1mM 
DTT, and 0.3 ug trypsin in a total volume of 100uL.  The supernatant was incubated 37C overnight 
and alkylated by addition of 8uL 0.5M iodoacetimate with 20 minutes incubation in the 
dark.  Samples were acidified by addition of 8uL 10% TFA and spun at 20000g. Peptides were 
loaded onto activated (15 uL methanol) equilibrated (50 uL 0.1 % TFA) stage tips, and washed 
with 50 uL 0.1 % TFA.  Elution in 80% acetonitrile 0.1 % TFA was followed by solvent removal 
in a vacuum concentrator, and volume then adjusted to 15 uL with 0.1 % TFA. Peptides were 
loaded onto a C18 packed emitter and separated on a 40 minute gradient from 3.6 % to 79 % 
acetonitrile with 0.5 % acetic acid throughout.  Data dependent acquisition was performed on a Q 
Exactive Plus with precursor scan 300-1650 70k resolution and fragmentation NCE 28.  Data was 
processed with MaxQuant v1.6.3.3 and Uniprot human proteome release 2018_09. Further 
technical details and raw data are available at ProteomeXchange with identifier PXD021270. 
 
Bioinformatics Methods 
RNA-seq pre-processing and analysis 
RNA sequencing reads were trimmed with Cutadapt (version 1.14) with default parameters and 
aligned to hg38 genome using the pseudo aligner Kallisto (version 0.43.1) (Martin, 2011; Bray et 
al., 2016). Read counts were summarised via the package Tximport (version 1.8.0) (Soneson et 
al., 2016) and subsequent normalisation was completed via DESeq2 (version 1.27.32) (Love et al., 
2014). Reported normalised read counts, unless otherwise stated, are as regularised-logarithm 
transformation (rlog) and are used for all downstream principle component analysis (PCA), 
clustering and visualisation (Love et al., 2014). Differential expression was completed with 
DESeq2 with log2 fold change (LFC) shrinkage (Love et al., 2014). GO enrichment analysis was 
completed with the R package clusterprofiler (version 3.15.4), using the Gene ontology (GO) 
database for Biological process (BP), where genes with non-zero read count were used as 
background (Harris et al., 2004; Yu et al., 2012). 
 
Derivation of forebrain hindbrain specific signatures 
Genes specific to forebrain or hindbrain tissue samples were identified via the Distal binarization 
approach as previously described (Corces et al., 2018). In brief, intra-group mean and standard 
deviations (SD) were calculated for each gene. Each gene group was then ranked by mean 
expression across replicates. For any gene where the mean expression of a group is higher than 3 
standard deviations than the group preceding it in rank, this gene is labelled specific to this sample 
group. All samples ranked higher than this group based on gene expression were also labelled as 
gene specific. Genes specific to forebrain or hindbrain samples were defined as genes specific to 
only these samples and no other groups. Three SD was chosen as a stringent threshold to 
accommodate low sample sizes. Pre-filtering of genes was completed using DESeq2 Likelihood 
Ratio test to filter out genes that were not significantly different across groups (FDR < 0.05). Genes 
were further filtered such that only specific genes that were also differentially expressed (FDR < 
0.05, LFC > 2), between forebrain and hindbrain, were retained. This process was repeated in cell 
line samples and a concise forebrain and hindbrain set was derived from the intersection of these 
two procedures.    
 
Derivation of regional signatures in cell line samples 
Regional signatures within forebrain (neocortex, striatum, diencephalon) and hindbrain 
(anterior/posterior brainstem, and spinal cord) NSC cultures were derived by completing 
differential expression between each individual group against all others using DESeq2 (FDR < 
0.05). Genes with low read count (< 1 read) across all samples were pre-filtered. Each set was 
permitted to overlap, and only the top 50 genes in each comparison, ranked by LFC, were chosen. 
Distal binarization was not utilised as samples were not distinct enough between each subgroup. 
Cerebellum and Midbrain signatures were not derived due to low or absent sample numbers (n=1, 
n=0 respectively). Anterior brainstem and posterior brainstem samples were merged due to high 
similarity. 
 
Affymetrix microarray pre-processing and analysis 
Affymetrix Human Genome U133 Plus 2.0 Array CEL files were downloaded for 3 separate 
studies from the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/) (GEO accessions: 
GSE34824, GSE36245, GSE19578) and re-processed using the oligo package (version 1.51.2), 
and rma normalisation in R (Carvalho et al., 2010). Pre-filtering of probes was completed by 
keeping probes with the highest variance across samples per gene annotation. Differential 
expression was completed using limma (version 3.43.11). Using knowledge of H3.3 mutations, 
batch correction was completed using the removeBatchEffect function in limma prior to data 
visualisation, clustering and PCA (Ritchie et al., 2015).     
 
Derivation of  pHGG G34 and K27 mutant signatures 
G34 and K27 signatures were derived by completing differential expression between each H3.3 
mutant group against all others (FDR < 0.1, top 50 genes). A higher FDR threshold was chosen to 
ensure a comparable gene set size to prior gene sets. As above differential expression was 
completed on rma normalised intensities using the package limma (Ritchie et al., 2015). 
 
Characterising samples with derived signatures 
Principal component analysis (PCA) was completed on pHGG samples using batch corrected rma 
normalised intensities, and NSC lines using normalised reads (rlog). Reciprocal gene sets were 
used in each PCA analysis whereby specific forebrain/hindbrain gene sets were used for pHGG 
samples, and G34/K27 gene sets were used in NSC samples. Reciprocal ssGSEA was completed 
on each sample set using forebrain/hindbrain, G34/K27, and additional regional signatures 
(neocortex, striatum, diencephalon, anterior/posterior brainstem and spinal cord) (Barbie et al., 
2009). For microarray and RNA-seq data ssGSEA was completed using the R package gsva 
(version 1.35.7), with the ssgsea method (Hänzelmann et al., 2013), on batch corrected rma 
intensities, and rlog normalised reads respectively. K-means consensus clustering was completed 
using the same samples and signatures described above with the R package ConsensusClusterPlus 
(version 1.52.0) (Monti et al., 2003; Wilkerson et al., 2010). Consensus clustering was run with 
10000 re-samples, a proportion of item and feature sampling of 0.7, with maximum k clusters of 
10 and 6 for NSC and pHGG samples respectively. Optimal k-clusters were chosen using the CDF 
(cumulative density function) of the consensus index across varying k clusters, and by inspecting 
the consensus matrix for each value of k. Consensus heatmaps were clustered by hierarchical 
clustering using Euclidean distance with average linkage criteria. 
 
Pediatric cBioPortal gene expression data 
Normalised expression (z-score) values of selected genes of interest were retrieved from the 
paediatric cBioPortal (https://pedcbioportal.kidsfirstdrc.org) using the Paediatric High Grade 
Glioma (ICR London, Cancer Cell 2017) study. Annotation of tumour location and H3.3 mutation 
status was retrieved together with gene expression values. Statistical analyses were performed 
using GraphPad Prism software.  
 
ChIP-seq pre-processing and analysis 
ChIP-seq reads were quality and adapter trimmed with Cutadapt, before being aligned to the 
human hg38 genome with bowtie2 (version 2.3.5) using default parameters (Martin, 2011; 
Langmead et al., 2012). Resulting BAM files were sorted and indexed with samtools and reads 
were filtered from ENCODE blacklist regions with samtools view (version 1.9) and bedtools 
intersect (version 2.29.0) (Li et al., 2009; Quinlan, 2014). PCR duplicates were filtered with picard 
tools MarkDuplicates (version 2.18.26) (Broad Institute, 2020). Peaks were called on filtered input 
and control BAM files with MAC2 set to broadPeak (H3.3, H3K36me3, H3K27me3), and 
narrowPeak (H3K4me3) (Zhang et al., 2008). Narrow peaks were called using MACS2 (version 
2.1.2) with the following command line parameters: macs2 callpeak -t Input.bam -c Control.bam 
-f BAMPE -g 2701495761 -s 50 --keep-dup all -B --SPMR --nomodel --shift 0 --extsize 146 -q 
0.05. Broad peaks were called with the additional parameters --broad --broad-cutoff 0.1 instead of 
-q 0.05. RPM normalised bedgraph files were generated via MACS2 following peak calling. 
Subtracted coverage files were generated using MACS2 bdgcmp between input and control BAMs. 
BigWig coverage files were generated using bedGraphToBigWig (version 4) from MACS2 
resulting bedgraphs (Kent et al., 2010). Where merged samples are reported, samtools merge was 
used on filtered BAMs across sample replicates before undergoing the same peak calling, 
bedgraph, and bigWig generation process. 
 
Heatmap and metagene plots were generated with deeptools (version 3.3.1) plotHeatmap and 
plotProfile respectively using subtracted bigWig files where negative values were set to 0 (Ramírez 
et al., 2014). Where deeptools metagene plots were completed across gene features these were 
based on the UCSC hg38 knownGene transcript model as defined by the 
TxDb.Hsapiens.UCSC.hg38.knownGene R package (version 3.4.0) (See Sequence feature 
analysis) (Team BC, 2016). Downregulated and Upregulated gene sets were defined as those 
significantly differentially expressed (FDR < 0.01) between pGBM002 parental and G34R-KO 
pGBM002 samples changing in the positive or negative direction. Expressed genes were defined 
as those with a mean RPKM < 1 across pGBM002 samples. 
 
Coverage of each histone mark over gene regions or genomic bins, for boxplots and scatterplots, 
were summarised using bedtools multicov on filtered and processed BAM files, and normalised to 
RPKM using gene or bin length. Histone mark log2 fold enrichment was calculated by taking the 
log2 fold change of RPKM for a given region between pGBM002 parental and G34R-KO 
pGBM002 samples. Quantiles of histone coverage and mRNA expression for each gene were 
calculated using RPKM normalised values.  
 
Peak overlaps between samples, and annotation, were completed using the R package 
ChIPpeakAnno (version 3.22.0) (Zhu et al., 2010). Promoter specific peaks were defined as those 
overlapping the transcription start site of a given gene +/- 2kb. Gene body peaks were defined as 
those peaks overlapping any portion of a gene region. Non overlapping shuffled G34R pGBM002 
parental peaks were generated using bedtools shuffle (Quinlan, 2014). 
 
Tracks of histone signal were created using IGV (version 2.8.2)  with merged and subtracted 
bigWig files (Thorvaldsdóttir et al., 2013).  
 
Sequence feature analyses 
Characterisation of sequence features across the genome were conducted using the UCSC hg38 
knownGene transcript model as defined by the TxDb.Hsapiens.UCSC.hg38.knownGene R 
package. Each gene region was defined by merging all overlapping transcripts for a given gene. 
For each gene, a single set of exons and introns were likewise defined by merging overlapping 
exons and introns separately. Transcripts with multiple discreet sites were filtered.  
Using this curated annotation GC% for each gene, exon, and intronic region was calculated using 
bedtools nuc (Quinlan, 2014). CpG island overlap was calculated as the percentage overlap of the 
CpG islands track from the UCSC genome browser with a given region. Observed-to-expected 
(o/e) CpG ratio was calculated for each gene, exon, or intronic region as previously defined 
(Gardiner-Garden et al., 1987). Exon density was calculated by counting exons per transcript, 
where overlapping exons were merged, and normalising for length. Gene wise exon and intron 
length were calculated as the sum of the merged exons or introns per gene region. 
Downregulated gene sets were defined as those significantly downregulated (FDR < 0.01) between 
pGBM002 parental and G34R-KO pGBM002 samples and those downregulated genes that 
overlapped with the “Forebrain Development” GO term. An empirical p-value for each sequence 
feature comparison between gene subsets and all genes was calculated using a resampling based 
approach. Where a null distribution was generated by randomly sub-sampling the genome (10,000 























Table 1 | List of genes and associated sample information used for clustering, principal 
component and gene set enrichment analyses. Related to Figure 1 
 
Table 1 | List of v5-H3.3 (WT and G34R) bound partners identified by IP-MS in patient cell 










Abbas, T., and Dutta, A. (2009). p21 in cancer: intricate networks and multiple activities. Nat. 
Rev. Cancer 9, 400–414. 
Ahmad, K., and Henikoff, S. (2002). The histone variant H3.3 marks active chromatin by 
replication-independent nucleosome assembly. Mol. Cell 9, 1191–1200. 
Barbie, DA. et al.  (2009). Systematic RNA interference reveals that oncogenic KRAS-driven 
cancers require TBK1. Nature. 462, 108–112. 
Bertacchi, M., Romano, A.L., Loubat, A., Mau-Them, F.T., Willems, M., Faivre, L., van Kien, 
P.K., Perrin, L., Devillard, D., Sorlin, A., et al. (2020). NR2F1 regulates regional progenitor 
dynamics in the mouse neocortex and cortical gyrification in BBSOAS patients. EMBO J 39(13): 
e104163. 
Bulstrode, H., Johnstone, E., Marqués-Torrejón, M.Á., Ferguson, K.M., Bressan, R.B., Blin, C., 
Grant, V., Gogolok, S., Gangoso, E., Gagrica, S., et al. (2017). Elevated FOXG1 and SOX2 in 
glioblastoma enforces neural stem cell identity through transcriptional control of cell cycle and 
epigenetic regulators. Genes Dev. 31, 757–773. 
Bjerke, L., Mackay, A., Nandhabalan, M., Burford, A., Jury, A., Popov, S., Bax, D., Carvalho, D., 
Taylor, K., et al. (2013). Histone H3.3 Mutations Drive Pediatric Glioblastoma through 
Upregulation of MYCN Cancer Discovery 3(5), 512-519. 
Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. (2016). Near-optimal probabilistic RNA-seq 
quantification. Nat. Biotechnol. 34, 525–527. 
Bressan, RB. et al. Efficient CRISPR/Cas9-assisted gene targeting enables rapid and precise 
genetic manipulation of mammalian neural stem cells. Development. 144, 635-648 (2017). 
Bushweller, T.H (2019) Targeting transcription factors in cancer - from undruggable to reality. 
Nat Rev Cancer 19(11):611-624. 
Carvalho, BS. et al. (2010). A framework for oligonucleotide microarray pre-
processing. Bioinformatics 26, 2363–2367. 
Castro, D.S., Skowronska-Krawczyk, D., Armant, O., Donaldson, I.J., Parras, C., Hunt, C., 
Critchley, J.A., Nguyen, L., Gossler, A., Göttgens, B., et al. (2006). Proneural bHLH and Brn 
proteins coregulate a neurogenic program through cooperative binding to a conserved DNA motif. 
Dev. Cell 11, 831–844. 
Chan, K., Fang, D., Gan, H., Hashizume, R., Yu, C., Schroeder, M., Gupta, N., Mueller, S., James, 
C.D., Jenkins, R., Sarkaria, J., Zhang, Z. (2013). The histone H3.3K27M mutation in pediatric 
glioma reprograms H3K27 methylation and gene expression. Genes Dev. 27(9): 985–990. 
Conti, L., Pollard, S.M., Gorba, T., Reitano, E., Toselli, M., Biella, G., Sun, Y., Sanzone, S., Ying, 
Q.L., Cattaneo, E., et al. (2005). Niche-independent symmetrical self-renewal of a mammalian 
tissue stem cell. PLoS Biol. 3, e283. 
Corces, M. R. et al. The chromatin accessibility landscape of primary human cancers. Science. 
362, eaav1898 (2018). 
Dewari, PS. et al.  An efficient and scalable pipeline for epitope tagging in mammalian stem cells 
using Cas9 ribonucleoprotein. eLife. e35069 (2018). 
Fang, D., Gan, H., Lee, J., Han, J., Wang, Z., Riester, S.M., Jin, L., Chen, J., Zhou, H., Wang, J., 
et al.(2016). The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas. 
Science 352(6291):1344-1348 
Filbin, M., and Monje, M. (2019). Developmental origins and emerging therapeutic opportunities 
for childhood cancer. Nat. Med. 25, 367–376. 
Funato, K., Major, T., Lewis, P.W., Allis, C.D., Tabar, V. (2014) Use of human embryonic stem 
cells to model pediatric gliomas with H3.3K27M histone mutation. Science 346(6216): 1529-
1533. 
Gardiner-Garden, M. and Frommer, M. (1987). CpG Islands in vertebrate genomes. J Mol Biol, 
196(2), pp. 261–282.  
Gibson, P., Tong, Y., Robinson, G., Thompson, M.C., Currle, D.S., Eden, C., Kranenburg, T.A., 
Hogg, T., Poppleton, H., Martin, J. et al. (2010) Subtypes of medulloblastoma have distinct 
developmental origins. Nature 468, 1095–1099. 
Goldberg, A., Banaszynski, L., Noh, K., Lewis, P., Elsaesser, S., Stadler, S., Dewell, S., Law, M., 
Guo, X., Li, X., et al. (2010). Distinct Factors Control Histone Variant H3.3 Localization at 
Specific Genomic Regions Cell 140(5), 678-691. 
Guo, R., Zheng, L., Park, J., Lv, R., Chen, H., Jiao, F., Xu, W., Mu, S., Wen, H., Qiu, J., Wang, 
Z., Yang, P., Wu, F., Hui, J., Fu, X., Shi, X., Shi, Y., Xing, Y., Lan, F., Shi, Y. (2014). 
BS69/ZMYND11 Reads and Connects Histone H3.3 Lysine 36 Trimethylation-Decorated 
Chromatin to Regulated Pre-mRNA Processing. Molecular Cell 56(2), 298-310. 
Hänzelmann, S. et al. (2013). GSVA: gene set variation analysis for microarray and RNA-Seq 
data. BMC Bioinformatics 14, 7. 
Harris, MA. et al. (2004). The Gene Ontology (GO) database and informatics resource. Nucleic 
Acids Res. 32, D258-61. 
Hennika, T., Hu, G., Olaciregui, N.G., Barton, K.L., Ehteda, A., Chitranjan, A., Chang, C., 
Gifford, A.J., Tsoli, M., Ziegler, D.S., et al. (2017). Pre-Clinical Study of Panobinostat in 
Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models. PLoS 
One 12, e0169485. 
Jessa, S., Blanchet-Cohen, A., Krug, B., Vladoiu, M., Coutelier, M., Faury, D., Poreau, B., De Jay, 
N., Hébert, S., Monlong, J., et al. (2019). Stalled developmental programs at the root of pediatric 
brain tumors. Nat. Genet. 51, 1702–1713. 
Johnson, R.A., Wright, K.D., Poppleton, H., Mohankumar, K.M., Finkelstein, D., Pounds, S.B., 
Rand, V., Leary, S.E.S., White, E., Eden, C. et al. (2010) Cross-species genomics matches driver 
mutations and cell compartments to model ependymoma. Nature 466, 632–636. 
Jones, C., Karajannis, M.A., Jones, D.T.W., Kieran, M.W., Monje, M., Baker, S.J., Becher, O.J., 
Cho, Y.-J., Gupta, N., Hawkins, C., et al. (2016). Pediatric high-grade glioma: biologically and 
clinically in need of new thinking. Neuro. Oncol. 19, 153–161. 
Kent, W. J., Zweig, A.S., Barber, G., Hinrichs, A.S., Karolchik, D. (2010). BigWig and BigBed: 
Enabling browsing of large distributed datasets. Bioinformatics. (17):2204-7. 
Khazaei, S., Jay, N.D., Deshmukh, S., Hendrikse, L.D., Jawhar, W., Chen, C.C., Mikael, L.G., 
Faury, D., Marchione, D.M., Lanoix, J., et al., (2020) H3.3G34W promotes growth and impedes 
differentiation of osteoblast-like mesenchymal progenitors in giant cell tumour of bone. Cancer 
Discovery. 10(12):1968-1987. 
Kitamura, K., Yanazawa, M., Sugiyama, N., Miura, H., Iizuka-Kogo, A., Kusaka, M., Omichi, K., 
Suzuki, R., Kato-Fukui, Y., Kamiirisa, K., et al. (2002). Mutation of ARX causes abnormal 
development of forebrain and testes in mice and X-linked lissencephaly with abnormal genitalia 
in humans. Nat. Genet. 32, 359–369. 
Konno, D., Iwashita, M., Satoh, Y., Momiyama, A., Abe, T., Kiyonari, H., and Matsuzaki, F. 
(2012). The mammalian DM domain transcription factor Dmrta2 is required for early embryonic 
development of the cerebral cortex. PLoS One 7, e46577. 
Langmead, B., Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2’. Nat Methods. 
9(4):357-9. 
Larson, J., Kasper, L., Paugh, B., Jin, H., Wu, G., Kwon, C., Fan, Y., Shaw, T., Silveira, A., Qu, 
et al. (2019). Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives 
Restricted Changes in Bivalent Gene Expression. Cancer Cell 35(1), 140-155.e7.  
Lewis, P.W., Muller, M.M., Koletsky, M.S., Cordero, F., Lin, S., Banaszynski, L.A., Garcia, B.A., 
Muir, T.W., Becher, O.J., and Allis, C.D. (2013). Inhibition of PRC2 Activity by a Gain-of-
Function H3 Mutation Found in Pediatric Glioblastoma. Science. 340(6134):857-861. 
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth,  G., Abecasis, G., 
Durbin, R., 1000 Genome Project Data Processing Subgroup (2009). The Sequence 
Alignment/Map format and SAMtools’. Bioinformatics, 25(16):2078-9. 
Love, MI. et al. (2014) Moderated estimation of fold change and dispersion for RNA-seq data with 
DESeq2. Genome Biol. 15, 550. 
Lu, C., Jain, S.U., Hoelper, D., Bechet, D., Molden, R.C., Ran, L., Murphy, D., Venneti, S., 
Hameed, M., Pawel, B.R., et al. (2016) Histone H3K36 mutations promote sarcomagenesis 
through altered histone methylation landscape. Science 352(6287): 844–849. 
Lujan, E., Chanda, S., Ahlenius, H., Südhof, T., Wernig, M. (2012). Direct conversion of mouse 
fibroblasts to self-renewing, tripotent neural precursor cells Proceedings of the National Academy 
of Sciences 109(7), 2527-2532.  
Mackay, A., Izquierdo, E., Bjerke, L., Nandhabalan, M., Temelso, S., Marshall, L., Zacharoulis, 
S., Bridges, L.R., Ng, H.-K., Li, X., et al. (2017). Integrated Molecular Meta-Analysis of 1,000 
Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell 32, 520–537.e5. 
Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing reads. 
EMBnet.journal, 17(1), 10. 
Mi, D., Carr, C.B., Georgala, P.A., Huang, Y.-T., Manuel, M.N., Jeanes, E., Niisato, E., Sansom, 
S.N., Livesey, F.J., Theil, T., et al. (2013). Pax6 exerts regional control of cortical progenitor 
proliferation via direct repression of Cdk6 and hypophosphorylation of pRb. Neuron 78, 269–284. 
Mohammad, F., and Helin, K. (2017). Oncohistones: drivers of pediatric cancers. Genes Dev. 31, 
2313–2324. 
Monteuuis, G., Wong, J.J.L., Bailey, C.G., Schimitz, U., Rasko, J.E.J. (2019) The changing 
paradigm of intron retention: regulation, ramifications and recipes. Nucleic Acids Research 
47(22):11497–11513. 
Monti, S., Tamayo, P., Mesirov, J., Golub, T. (2003). Consensus clustering: A resampling-based 
method for class discovery and visualization of gene expression microarray data. Mach. Learn. 52, 
91–118 (2003). 
Ono, K., Takebayashi, H., Ikeda, K., Furusho, M., Nishizawa, T., Watanabe K., Ikenake K. (2008) 
Regional- and temporal-dependent changes in the differentiation of Olig2 progenitors in the 
forebrain, and the impact on astrocyte development in the dorsal pallium. Developmental Biology 
320(2)-456-468 
Pathania, M., De Jay, N., Maestro, N., Harutyunyan, A.S., Nitarska, J., Pahlavan, P., Henderson, 
S., Mikael, L.G., Richard-Londt, A., Zhang, Y., et al. (2017). H3.3K27M Cooperates with Trp53 
Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-
Grade Gliomas. Cancer Cell 32, 684–700.e9. 
Paugh, B.S., Qu, C., Jones, C., Liu, Z., Adamowicz-Brice, M., Zhang, J., Bax, D.A., Coyle, B., 
Barrow, J., Hargrave, D., et al. (2010). Integrated molecular genetic profiling of pediatric high-
grade gliomas reveals key differences with the adult disease. J. Clin. Oncol. 28, 3061–3068. 
Pevny, L., and Placzek, M. (2005). SOX genes and neural progenitor identity. Curr. Opin. 
Neurobiol. 15, 7–13. 
Pollard, SM. (2009) et al. Glioma stem cell lines expanded in adherent culture have tumor-specific 
phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell. 4, 568-580. 
Quinlan, A. R. (2014). BEDTools: The Swiss-Army Tool for Genome Feature Analysis. Curr. 
Protoc. Bioinformatics. 47:11.12.1-34. 
Ramírez, F., Dundar, F., Diehl, S., Gruning, B.A., Manke, T. (2014). DeepTools: A flexible 
platform for exploring deep-sequencing data. Nucleic Acids Res. 42(W1): W187-W191.  
Ritchie, ME.  et al. (2015)  limma powers differential expression analyses for RNA-sequencing 
and microarray studies. Nucleic Acids Res. 43, e47. 
Salloum, R., McConechy, M.K., Mikael, L.G., Fuller, C., Drissi, R., DeWire, M., Nikbakht, H., 
DeJay, N., Yang, X., Boue, D., et al. (2017) Characterizing temporal genomic heterogeneity in 
pediatric high-grade gliomas. Acta Neuropathol Commun 5(1):78. 
Shechter, D., Dormann, H.L., Allis, D.C., Hake, S.B. (2007). Extraction, purification and analysis 
of histones. Nat Protocols. 2(6):1445-57.  
Schwartzentruber, J., Pfaff, E., Jacob, K., Sturm, D., Tönjes, M., Konermann, C., Lindroth, A., 
Jäger, N., Rausch, T., Korbel, J.O., et al. (2012). Driver mutations in histone H3.3 and chromatin 
remodelling genes in paediatric glioblastoma. Nature 482, 226–231. 
Seoane, J., Le, H.-V., Shen, L., Anderson, S.A., and Massagué, J. (2004). Integration of Smad and 
forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117, 
211–223. 
Siegenthaler, J.A., Tremper-Wells., B.A., Miller, M.W (2008) Foxg1 haploinsufficiency reduces 
the population of cortical intermediate progenitor cells: effect of increased p21 expression. Cereb. 
Cortex 18, 1865–1875.  
Soneson, C., Love, M.I., Robinson, M.D. (2016). Differential analyses for RNA-seq: transcript-
level estimates improve gene-level inferences. F1000 Res. 4, 1521. 
Steinfeld, H., Cho, M.T., Retterer, K., Person, R., Schaefer, G.B., Danylchuk, N., Malik, S., 
Wechsler, S.B., Wheeler, P.G., van Gassen, K.L.I., et al. (2016). Mutations in HIVEP2 are 
associated with developmental delay, intellectual disability, and dysmorphic features. 
Neurogenetics 17, 159–164. 
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D.T.W., Konermann, C., Pfaff, 
E., Tönjes, M., Sill, M., Bender, S., et al. (2012). Hotspot mutations in H3F3A and IDH1 define 
distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22, 425–437. 
Sun, Y., Pollard, S., Conti, L., Toselli, M., Biella, G., Parkin, G., Willatt, L., Falk, A., Cattaneo, 
E., and Smith, A. (2008). Long-term tripotent differentiation capacity of human neural stem (NS) 
cells in adherent culture. Mol. Cell. Neurosci. 38, 245–258. 
Thorvaldsdóttir, H., Robinson, J.T, Mesirov, J.P. (2013). Integrative Genomics Viewer (IGV): 
high-performance genomics data visualization and exploration. Brief Bioinform. (2):178-92. 
Valencia, A.M., and Kadoch, C. (2019). Chromatin regulatory mechanisms and therapeutic 
opportunities in cancer. Nat. Cell Biol. 21, 152–161. 
Veloso, A., Kirkconnell, K.S., Magnuson, B., Biewen, B., Paulsen, M.T., Wilson, T.E., Ljungman, 
M. (2014) Rate of elongation by RNA polymerase II is associated with specific gene features and 
epigenetic modifications. Genome Res. 24(6): 896–905. 
Verginelli, F., Perin, A., Dali, R., Fung, K.H., Lo, R., Longatti, P., Guiot, M.-C., Del Maestro, 
R.F., Rossi, S., di Porzio, U., et al. (2013). Transcription factors FOXG1 and Groucho/TLE 
promote glioblastoma growth. Nat. Commun. 4, 1–16. 
Vladoiu, M.C., El-Hamamy, I., Donovan, L.K., Farooq, H., Holgado, B.L., Sundaravadanam, Y., 
Ramaswamy, V., Hendrikse, L.D., Kumar, S., Mack, S.C., et al. (2019). Childhood cerebellar 
tumours mirror conserved fetal transcriptional programs. Nature 572, 67–73. 
Voon, H.P.J., Udugama, M., Lin, W., Hii, L., Law, R.H.P., Steer, D.L., Das, P.P., Mann, J.R., and 
Wong, L.H. (2018). Inhibition of a K9/K36 demethylase by an H3.3 point mutation found in 
paediatric glioblastoma. Nat. Commun. 9, 3142. 
Weinberg, D.N., Allis, C.D., and Lu, C. (2017). Oncogenic Mechanisms of Histone H3 Mutations. 
Cold Spring Harb. Perspect. Med. 7, a026443. 
Wilkerson, M.D et al. (2010). ConsensusClusterPlus: A class discovery tool with confidence 
assessments and item tracking. Bioinformatics. 26, 1572–1573. 
Wu, G., Broniscer, A., McEachron, T.A., Lu, C., Paugh, B.S., Becksfort, J., Qu, C., Ding, L., 
Huether, R., Parker, M., et al. (2012). Somatic histone H3 alterations in pediatric diffuse intrinsic 
pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 44, 251–253. 
Xuan, S., Baptista, C.A., Balas, G., Tao, W., Soares, V.C., and Lai, E. (1995). Winged helix 
transcription factor BF-1 is essential for the development of the cerebral hemispheres. Neuron 14, 
1141–1152. 
Wen, H., Li, Y., Xi, Y., Jiang, S., Stratton, S., Peng, D., Tanaka, K., Ren, Y., Xia, Z., Wu, J., Li, 
B., Barton, M., Li, W., Li, H., Shi, X. (2014). ZMYND11 links histone H3.3K36me3 to 
transcription elongation and tumour suppression. Nature 508(7495), 263-268.  
Yip, D.J., Corcoran, C.P., Alvarez-Saavedra, M., DeMaria, A., Rennick, S., Mears, A.J., Rudnicki, 
M.A., Messier, C., Picketts, D.J. (2012) Snf2l Regulates Foxg1-Dependent Progenitor Cell
Expansion in the Developing Brain. Dev Cell 22(4): 871–878.
Yoshida, M., Suda, Y., Matsuo, I., Miyamoto, N., Takeda, N., Suratani, S., Aizawa, S. (1997). 
Emx1 and Emx2 functions in development of dorsal telencephalon. Development 124(1): 101-
111. 
Young, F.I., Keruzore, M., Nan, X., Gennet, N., Bellefroid, E.J., and Li, M. (2017). The doublesex-
related Dmrta2 safeguards neural progenitor maintenance involving transcriptional regulation of 
Hes1. Proc. Natl. Acad. Sci. U. S. A. 114, E5599–E5607. 
Yu, G., Wang, L., Han, Y,. He., Q. (2012) ClusterProfiler: an R Package for Comparing Biological 
Themes Among Gene Clusters. Omi. A J. Integr. Biol. 16, 284–287. 
Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute., J., Johnson, D.S., Bernstein, B.E., Nusbaum., C., 
Myers, R.M., Brown, M., Li., W., Liu, X.S.,  (2008). Model-based analysis of ChIP-Seq (MACS). 
Genome Biol. 9(9):R137. 
Zhang, Y., Shan, C., Wang, J., Bao, K., Tong, L., Jia, S., (2017). Molecular basis for the role of 
oncogenic histone mutations in modulating H3K36 methylation. Sci Rep. 7: 43906. 
Zhu, L. J., Gazin, C., Lawson, N.D, Pages, H., Lin, S.M., Lapointe, D.S., Green, M.R. (2010). 
ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC 
Bioinformatics. 11:237 
Zweifel, S., Marcy, G., Guidice, Q.L., Li, D., Heinrich, C., Azim, K., Raineteau, O. (2018) HOPX 
Defines Heterogeneity of Postnatal Subventricular Zone Neural Stem Cells. Stem Cell Reports 
















































































1 2 3 4 5 6 7 8 1 2 3 5 7 86
+3 -30
Z-Score
Tissue reference NSCs lines
Cell dissociation











GCGR-NS19 - 19.3 pcw
GCGR-NS13 - 13.5 pcw


























81 2 3 6
7




Gene set G34 K27 Forebrain Hindbrain
pHGG type
Gene set


















































































−20 −10 0 10 20
Tissue reference + NSC lines
Top 500 variable genes
D
0 10 20 30 40
neuron fate commitment
central nervous system neuron differentiation









0 5 10 15 20




regulation of synaptic plasticity
regulation of membrane potential
neurotransmitter transport
synapse organization
regulation of trans-synaptic signaling


























































































































































































































































































































































































































































n.s n.s n.s n.s













































































n.s n.s p<0.1 p<0.01








































































































































0 60 120 180 240 300
H3F3A  locus - pGBM002 cell line
Ala Thr Lys Ala Ala Arg Lys Ser Ala Pro Ser Thr Gly Gly Val Lys Lys Pro His Arg Tyr
CCCGCAAATCGACCGGTGGTAAAGCACCCAGGAAGCAAC T G GCTACAAAAGCCGCTCGC A A GAGTGCGCCCTCTACTGG A G GGGTGAAGAAACCTCATCGTT A C
GGGCGTTTAGCTGGCCACCATTTCGTGGGTCCTTCGTTG A C CGATGTTTTCGGCGAGCGTTCTCACGCGGGAGATGACCTTCCCACTTCTTTGGAGTAGCAA T G
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ala Thr Lys Ala Ala Arg Lys Ser Ala Pro Ser Thr Gly Arg Val Lys Lys Pro His Arg Tyr
CCCGCAAATCGACCGGTGGTAAAGCACCCAGGAAGCAAC T G GCTACAAAAGCCGCTCGC A A GAGTGCGCCCTCTACTGG A a GGGTGAAGAAACCTCATCGTT A C

















WT H3F3A  allele
G34R H3F3A allele
GCTACAAAAGCCGCTCGC A A GAGTGCGCCCTCTACTGG A G GGGTGAAGAAACCTCATCGTT A C
CGATGTTTTCGGCGAGCGTTCTCACGCGGGAGATGACCTCCCCACTTCTTTGGAGTAGCAA T G
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GCTACAAAAGCCGCTCGC A A GAGTGCGCCCTCTACTGG A a GGGTGAAGAAACCTCATCGTT A C
CGATGTTTTCGGCGAGCGTTCTCACGCGGGAGATGACCTTCCCACTTCTTTGGAGTAGCAA T G
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GCTACAAAAGCCGCTCGC A A GAGTGCGCCCTCTACTGG A G GGGTGAAGAAACCTCATCGTT A C
CGATGTTTTCGGCGAGCGTTCTCACGCGGGAGATGACCTCCCCACTTCTTTGGAGTAGCAA T G
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GCTACAAAAGCCGCTCGC A A GAGTGCGCCCTCTACTGG - a GGG TGAAGAAACCTCATCGTT A C






































































































































































































































































































neural precursor cell proliferation



















0.0 2.5 5.0 7.5
− 10 (p.adj)
10
positive regulation of cellular
 component movement
positive regulation of locomotion
positive regulation of cell motility














































































































































































-5 TSS TES +5
gene distance (kb)
















-5 TSS TES +5
gene distance (kb)









































-10kb Peak center +10kb
G34R-KO peaks








Common peaksParental peaks G34R-KO peaks








































































-5 TSS TES +5
gene distance (kb)













-5 TSS TES +5
gene distance (kb)




























































































































































































































































































































































Downregulated - All (n=475)










































































































































































































CpG content CpG island content
****
***
**** *** *** **
****
******* ****














































































Parental (n = 9)
FOXG1-KO (n = 3)
FIG.7
Z-
sc
or
e
G
FP
D
AP
I
Ne
oc
or
te
x
Br
ai
ns
te
m
pG
BM
00
2
aG
BM
7
aG
BM
31
3
FOXG1 mRNA
 
H
10 0
10 2
10 4
10 6
G34R 
pGBM002 aGBM7
WT
aGBM313
WT
Pa
re
nt
al
FO
XG
1-
KO
p21
GAPDH
FOXG1
I
K
0
15
30
45
60
n.s
Pa
re
nt
al
FO
XG
1-
KO
Ed
U
+ 
ce
lls
 (%
)
Pa
re
nt
al
FO
XG
1-
KO
Pa
re
nt
al
FO
XG
1-
KO
0
15
30
45
60
***
0
15
30
45
60
n.s
0
2
4
6
8
0
2
4
6
8
0
2
4
6
8
J
Pa
re
nt
al
FO
XG
1-
KO
Pa
re
nt
al
FO
XG
1-
KO CDKN1A mRNA
Pa
re
nt
al
FO
XG
1-
KO
Pa
re
nt
al
FO
XG
1-
KO
Pa
re
nt
al
FO
XG
1-
KO
G34R 
pGBM002 aGBM7
WT
aGBM313
WT
CB
0
40
60
80
100 50
Pa
re
nt
al
FO
XG
1-
KO
Pa
re
nt
al
FO
XG
1-
KO
  (
%
)
L
0
2
4
6
8
10
*
0
2
4
6
8
10
0
2
4
6
8
10
n.s
Pa
re
nt
al
FO
XG
1-
KO
Pa
re
nt
al
FO
XG
1-
KO
Pa
re
nt
al
FO
XG
1-
KO
G34R 
pGBM002
G34R 
pGBM002aGBM7
WT
aGBM7
WT
aGBM313
WT
aGBM313
WT
20
Re
la
tiv
e 
ex
pr
es
sio
n
Re
la
tiv
e 
ex
pr
es
sio
n
n.s
-15
-10
-5
0
+5
+10
+15
He
m
isp
he
ric
W
T-
H3
.3
He
m
isp
he
ric
G
34
R-
H3
.3
M
id
lin
e
Br
ai
ns
te
m
n.s
FOXG1 mRNA
 
****
n.s n.s**
i ur
